University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2017

Characterizing reactive glutamines in fibrinogen and elucidating
factor XIII substrate specificity.
Kelly Njine Mouapi
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Biochemistry Commons, and the Laboratory and Basic Science Research Commons

Recommended Citation
Mouapi, Kelly Njine, "Characterizing reactive glutamines in fibrinogen and elucidating factor XIII substrate
specificity." (2017). Electronic Theses and Dissertations. Paper 2770.
https://doi.org/10.18297/etd/2770

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the
author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN AND
ELUCIDATING FACTOR XIII SUBSTRATE SPECIFICITY

By
Kelly Njine Mouapi
B.A., Berea College, 2012
M.S., University of Louisville, 2015

A Dissertation
Submitted to the Faculty of the
College of Arts and Sciences of the University of Louisville
in Partial Fullfillment of the Requirements
for the Degree of

Doctor of Philosophy in Chemistry

Department of Chemistry
University of Louisville
Louisville, Kentucky

August 2017

Copyright 2017 by Kelly Mouapi

All rights reserved

CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN AND
ELUCIDATING FACTOR XIII SUBSTRATE SPECIFICITY
By
Kelly Njine Mouapi
B.A., Berea College, 2012
M.Sc., University of Louisville, 2015
A Dissertation Approved on

June 28th, 2017

by the following Dissertation Committee:
______________________________________________
Dissertation Chair
Dr. Muriel Maurer
______________________________________________
Dr. Michael Merchant
_______________________________________________
Dr. Eugene Mueller
_______________________________________________
Dr. Richard Wittebort

ii

DEDICATION
This dissertation is dedicated to my grandmother Mrs Agnes Wubnyonga Fokong
who nurtured my love for science at a tender age, sacrificed a lot so that I could
obtain an education and excel as a student, and encouraged me to pursue my
dreams
To
My deceased aunt Ms Mercy Fokong Nukanjam whose death from a sudden
heart attack in 2004 fueled my passion for cardiovascular disease research
To
My family especially my parents Mr Hilaire Tsozock and Mrs Hope Nunyonga
Tsozock, my aunt Flora Bidgemia, Ms Kathy Carr and Mr David Moore who
equipped me with valuable life skills
To
My siblings Dingbobga Terence, Touoyem Ningha Mimi-Sylvie, Bradley Beckley,
Nyonkaa Larissa, and KenDenzel Tsozock. You fill my life with laughter and
purpose
and
To my love and life partner Mr. Jonathan Davis. Words cannot describe the
impact you have had in my personal and professional growth. You believed in
me. You cheered me on all along the way. Thank you!

iii

ACKNOWLEDGMENTS
As an old adage goes “It takes a village to raise a child” ~ African Proverb. I
would like to thank the village that supported me through this journey with words
of encouragement, resources, feedback and ideas that led to this dissertation.
I acknowledge my Ph.D. advisor and mentor Dr. Muriel Maurer for making this
journey worthwhile. I am very grateful for your guidance through my graduate
career and for mentoring me each step of the way. Your knowledge and
expertise in the field of blood coagulation sparked my interests in this research.
Your commitment to this research topic encouraged me to be just as committed,
and your mentorship fostered my growth as a young investigator. You
encouraged and helped me attend international conferences at an early stage
during my career, which helped me to become a part of the scientific community
in thrombosis. Thank you for supporting me, my passion for this research, and for
sharing existing opportunities for professional growth with me.
A special thank you to my dissertation committee members for all your guidance,
advice, training, and help. Thank you Dr. Eugene Mueller for making Enzymology
so intriguing through your lectures and discussions. I learned a lot from your
teaching style and aspire to impart other students like you did for me. Thank you
Dr. Richard Wittebort for sharing your expertise in Protein NMR and for always
being available to help. Thank you Dr. Michael Merchant for your insight
throughout this research and especially for contributing to the progress of this
dissertation with the LC-MS approach.
I would like to acknowledge a multitude of people who have trained me
voluntarily throughout my time as a graduate student. I would like to thank Mr.
Daniel Wilkey for his time, commitment to my experiments, and patience in
teaching me how to use the Skyline software. Dr. Nazimuddin Nazimuddin for his
contributions and training with plasmid design, protein expression, and also his
valuable friendship. Thank you Dr. T Michael Sabo for your help with IPAP
experiments and the 800 MHz NMR and Dr. Neal Stolowich for your help working
with the 700 MHz NMR. I would like to acknowledge Mr. Jason Blumenkemp (JBI
scientific) for his training on MALDI TOF hardware and his time. I would like to
especially thank Mr. Steve Riley. I learned a lot from you and your commitment to
making sure things worked.
I am extremely grateful to Dr. Leonid Medved, Dr. Jeffrey Keillor, and Dr. Kerrie
Smith for DNA samples and advice. I extend a special thanks to Dr. Helen
Philippou and Dr. Robert Arïens for sharing their expertise with me. Thank you
iv

Dr. Aleeta Powe for your mentoring and friendship. I would like to thank past
members of the Maurer Lab: Dr. Marina Malovichko, Jacob Bell, Blake Lynch,
Camela Riposo, Sara Zink, Chad Stephens and ENSCM (Montpellier) exchange
student Lucille Wagner.
I would like to thank all my colleagues and new friends here at UofL. Dr. Elisha
Otome and Dr. Sakatali Gori for guiding me. Ramya Billur, thank you for your
friendship, advice, help, and support. Boris Anokhin thank you for all you do. I
would like to acknowledge Mumiye Ogunwale for his friendship and being each
other’s keeper. To my friends and cohort members Wuyu Zhang, Rahul Jain,
Andrew Haddad and Sara Biladeau. Thank you for your support. Many thanks to
Ms Nalley Sherry and Ms Sabrina Haug for their hardwork with graduate
students, and to the CGSA for organizing the Nobel Laureate Derby Lectures.
I would like to especially thank the Public Safety and escort service team at UofL
for this innitiative. I could work late nights in the lab knowing that I had a safe and
free ride home. Thank you! To the Minority Association of Graduate Students
(M.A.G.S), thank you. To some very special mentors Ms Prafula Sheth and
Pastor Mr. & Mrs Akenroye, thank you all. To my church family at RCCG Agape
house, you are appreciated.
To my family, especially my grandmother who helped me to discover my love for
science, thank you for your words of encouragements. I acknowledge Berea
College for amazing opportunities to explore scientific research as a career
option. To all faculty and staff of the Department of Chemistry.
I would like to acknowledge my love and life partner Mr. Jonathan Davis for his
support, advice, guidance, and love. Words are not enough to express my
gratitude. Thank you!

v

ABSTRACT
CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN AND
ELUCIDATING FACTOR XIII SUBSTRATE SPECIFICITY
Kelly Njine Mouapi
June 28, 2017
Fibrinogen is the most abundant protein involved in blood coagulation and
has been associated with many pathological implications in cardiovascular
disease. At the final stages of blood clot formation, the transglutaminase Factor
XIIIa introduces γ-glutamyl-ε-lysinyl covalent bonds between reactive glutamines
and lysines in fibrin, which results in a tighter clot network that is resistant to
fibrinolysis. Factor XIIIa crosslinks specific reactive glutamines on fibrinogen,
selecting more reactive glutamines in the αC region of fibrinogen than any other
chain. Although crosslinking pairs in the αC region have been identified, little is
known about the extent of crosslinking and the role played by each reactive
glutamine.
For the first time, we have ranked three reactive glutamines crosslinked
under

physiological

conditions.

spectrometry, LC-MS, and 2D

15

A

combination

of

MALDI-TOF

mass

N-1H HSQC NMR studies was used on

Fibrinogen αC(233-425) to understand Factor XIIIa’s substrate specificity. Factor
vi

XIIIa’s specificity for each reactive glutamine in αC(233-425) was monitored by
the enzyme's ability to cross-link a lysine mimic, glycine ethyl ester (GEE), to the
reactive glutamines (Q237, Q328, Q366). We showed that Factor XIIIa crosslinks
these three glutamines to GEE in the order Q237 >> Q366 ≈ Q328.
Fibrinogen αC(233-425) variants were generated in which each reactive
glutamine (Q) was replaced with an inactive asparagine (N). We demonstrated
that Factor XIIIa still crosslinks each reactive glutamine independently and is
more selective in the absence of the most reactive glutamine Q237. To examine
the role of the putative Factor XIII binding site on αC(233-425), we performed
experiments in which an important amino acid E396 was replaced with an
alanine (Fbg αCE396A). Our results showed that both plasma Factor XIII A2B2
and recombinant Factor XIII A2 can crosslink all three reactive glutamines in Fbg
αCE396A to a similar extent as with the WT.
For structural characterization, αC(233-425) was expressed in
15

15

N/13C-enriched media. 2D HSQC NMR experiments confirmed that the

labeled αC(233-425) is mostly intrinsically disordered.

N or
15

N-

Residues surrounding

Q366 and Factor XIII's binding site αC(389-402) showed a higher propensity for
order. 2D NMR experiments suggest the possibility of pre-structured motifs
(PreSMOS) within Fibrinogen αC(233-425).
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CHAPTER 1
INTRODUCTION

The formation of a blood clot is triggered by the body’s need to prevent
excessive bleeding, eliminate foreign bodies and prevent infection especially
following an injury.1 Blood clots create a plug at the site of injury preventing
excessive bleeding and provide a barrier against infection, a process known as
haemostasis. Thrombosis is the formation of a blood clot within a blood vessel
following injury. The major components in a clot include; platelets, red blood
cells, white blood cells, and the fibrin(ogen) network.2-4 Not to our surprise, the
mode of recruiting, activating, sustaining and subsequently, terminating the
clotting process are very interconnected and tightly controlled by both cellular
and molecular components. These processes leading to the formation of a stable
blood clot can be divided into four major categories: initiation, propagation,
amplification, and stabilization.1, 3 Several proteins and enzymes are involved in
these processes summarized in the blood coagulation cascade described below.

1

The Blood Coagulation Cascade
Upon injury, the extracellular matrix layer is exposed which triggers the
initiation phase in blood coagulation.5 One of the major components recruited
during the initiation phase are platelets.2 Platelets are produced in the liver and
circulate freely in the plasma. The exposure of extracellular matrix during an
injury triggers a series of events that recruits platelets to the site.2 The membrane
surface of platelets contains glycoproteins that bind to specific ligands in the
vessel wall.6 This interaction promotes platelet adhesion and aggregation to form
a platelet plug at the site of injury.1 Platelets are therefore known to provide
primary haemostasis since they make up the first mechanism of defense at the
site of injury.
Secondary haemostasis is provided by plasma coagulation factors triggered
by Tissue Factor (TF) – another major component involved during the clot
initiation phase. This integral membrane protein is also activated upon
extracellular matrix exposure and contact with plasma.5 TF plays a crucial role in
initiating the cascade of enzymatic processes that are later involved in the
propagation, amplification, and stabilization of a clot.7 The blood coagulation
cascade is commonly used to represent the enzymes, proteins and cofactors
involved in this process (Figure 1).

2

Figure 1: The Blood Coagulation Cascade showing the contact factor pathway (intrinsic pathway), tissue
factor pathway (extrinsic pathway) and common pathway (from Factor Xa). Roman numerals are used to
represent enzymes and appended with “a” to illustrate activation

Blood clots are formed following a series of events involving several enzymes
organized as a cascade. The blood coagulation cascade can be initiated via two
pathways: the intrinsic and extrinsic pathways (Figure 1). The intrinsic or contact
pathway is less common and activated via negatively charged molecules
including naturally occurring extracellular nucleic acids and polyphosphates,
misfolded proteins, and negative artificial surfaces e.g glass, silica.8 The extrinsic
or tissue factor pathway is activated upon injury. Both the intrinsic and extrinsic
cascades merge and proceed through the “common pathway”.9 Although the
biochemistry leading up to the formation of the clot has been extensively studied,
3

there are still many unanswered questions especially pertaining to the modes of
regulation and target for each enzyme involved in this cascade.
The blood coagulation cascade is made up mainly of serine proteases Factor
II –XII (numbered in roman numerals according to their order of discovery and
not their role in the cascade).5 These enzymes are involved in defined processes
leading up to the formation of a stable blood clot. Fibrinogen (Factor I) and Factor
XIII are the only two proteins in the cascade that are not serine proteases.1 Most
enzymes in the cascade exist in their inactive zymogen states and require one or
more components for activation (denoted with “a” upon activation e.g II to IIa).
Calcium (Ca 2+) serves as a cofactor to a majority of the enzymes and is required
for the activation of most zymogens in the cascade (Figure 1). For example,
calcium is critical in the activation of the transglutaminase Factor XIII found at the
final stage.10,

11

Activated Factor XIII is responsible for introducing crosslinks

within the clot and crosslinking other components needed to stabilize the clot.12,
13

As expected, a tight regulation in this cascade leading to a stable blood clot

formation is needed to maintain homeostasis. A disruption in one or more of the
enzymes in the cascade can lead to detrimental effect.
The intrinsic or contact factor pathway is initiated in response to a host
pathogen defense mechanism and is triggered by negatively charged surfaces
and components (e.g excessive DNA, polyphosphates, misfolded proteins, glass,
silica, etc). Contact with artificial surfaces e.g cardiopulmonary bypass,
extracorporeal membrane oxygenation (ECMO), and hemodialysis, have also
been shown to trigger the intrinsic pathway (Figure 1).
4

1, 7

There has recently

been a renewed interest in Kallikrien research, particularly pertaining to its role in
the formation of Factor XII and possible implications in thrombosis in cancer
patients.14 In cancer for example, where there are numerous indications of
excessive DNA, it is proposed that the presence of these negatively charged
bodies promote activation of Factor XII leading to an overproduction of the blood
coagulation cascade components.8,

15

In the propagation phase of coagulation,

activated Factor XII promotes the activation of Factor XI in the presence of Ca2+.
This in turn activates Factor IX. It should be noted here that Hemophilia B is a
result of deficiency in Factor IX.16 Meanwhile, Haemophilia A is as a result of a
deficiency in Factor VIII in the Tissue factor pathway or extrinsic pathway.1
The extrinsic or tissue factor pathway is predominant in tissue damage i.e in
the wound healing process. This occurs externally and leads the formation of a
thrombus if the damage is within a blood vessel. This pathway is named after the
tissue factor responsible for initiating this process.1 Tissue factor together with
Factor VII form the (TF: VIIa) complex. In the propagation phase, this complex
activates Factor IX and Factor X which leads to a large burst of thrombin for the
common pathway.5 Both the intrinsic and extrinsic pathways contribute to the
activation of Factor Xa, and ultimately lead to increased production of thrombin
for the common pathway (Figure 1).7
In the common pathway, Factor Xa activates Prothrombin (Factor II) to
Thrombin (II). Thrombin is one of the major proteins involved in the formation of
blood clots and has been studied extensively for drug design. Thrombin is also
responsible for creating the positive feedback effect in blood coagulation by
5

activating many other clotting factors. Thrombin activates Factor V, Factor VIII,
Factor XIII and Fibrinogen, amplifying these components of the coagulation
cascade. This amplification results in the production of more Factor Xa and, in
turn, more thrombin is generated. This positive feedback by thrombin sustains
clot production in the amplification phase.5 Such an amplification is also seen in
platelets whereby, thrombin activates platelets surfaces and the components that
promote further platelet aggregation including platelet activated receptors (PARs)
and the glycoprotein (GpIbα).17 Activated platelets aggregate effectively with the
help of a fibrin layer from fibrinogen (Factor I). Through limited proteolysis,
thrombin cleaves fibrinogen to the form fibrin monomers during the stabilization
phase of blood coagulation cascade.

Figure 2: Key players at the final stabilization stage of the Blood Coagulation cascade

6

The stabilization stage, also referred herein as the final stage of the blood
coagulation cascade, is composed of three major players: thrombin, fibrinogen
and Factor XIII (Figure 2). Thrombin converts fibrinogen to its active form fibrin.
This active fibrin self-polymerizes into a fibrous network.18 The meshy fibrin
network forms the mold of a clot, provides an anchoring surface for platelets, and
traps red blood cells and other enzymes needed for clot stability.5 To further
stabilize the clot, thrombin activates Factor XIII, a transglutaminase which
introduces covalent bonds within the fibrin clot network. Factor XIII also
crosslinks inhibitors that prevent clot degradation.19 Overall, thrombin plays a
crucial role in connecting several clotting components at the later stage of the
clotting cascade. Thrombin has therefore been viewed as a critical enzyme for
researchers and in the pharmaceutical industry.
Several anticoagulant and procoagulant drugs designed to treat heart
disease conditions target steps leading up to the formation of thrombin or
thrombin itself.20 Typically these drugs often have a high bleeding risk as their
side effects. As expected, targeting and inhibiting thrombin also affects all other
clotting factors that rely on thrombin for their activation. Nonetheless, nature has
provided mechanisms to control excessive bleeding and insufficient clotting.
Inhibitors are harbored in the vascular endothelium and released, as needed, to
regulate haemostasis. For example, antithrombin inhibits thrombin and indirectly
inhibits Factor Xa, IXa, and XI in the intrinsic pathway.1, 3 Tissue factor plasmin
inhibitor (TFPI) is stored in platelets and inhibits the extrinsic pathway. The tight
network formed by fibrin and Factor XIII is also degraded through a process
7

known as fibrinolysis. This process is characterized by the cleavage of fibrin into
fibrin degradation products by the enzyme plasmin. Tissue plasmin activator
(tPA) activates plasmin from its inactive form, plasminogen. Inhibitors of tPA
have been designed and are currently being used to prevent fibrinolysis in cases
of excessive bleeding.21 Another mechanism of regulation is through Protein C.
Thrombomulin-bound thrombin accelerates Protein C activation. Activated
Protein C (APC), inhibits several clotting enzymes including Factor Va and Factor
VIIIa.7 Although nature’s procoagulant and anticoagulant mechanisms are in
place, these mechanisms do not suffice in the case of deficiencies affecting key
players in the blood coagulation cascade. Disrupting any stage of this process
can lead to pathological thrombosis or haemorrhage. There is a significant gap in
the research and drug designs that target enzymes beyond thrombin.
Deficiencies especially in fibrinogen and Factor XIII are growing and have
posed a unique challenge in drug discovery. Researchers in this field are
constantly searching and improving knowledge about biomarkers, tools, and
drugs specific to each problem-causing enzyme in the cascade. In this research,
fibrinogen (Factor I) and Factor XIII are studied to understand their interplay at
the final stage of the blood coagulation cascade. The next sections that follow
will focus on structural and functional properties of fibrinogen and Factor XIII as
examined for the purposes of this dissertation.

8

Fibrinogen
Fibrinogen is found in the blood plasma of all vertebrates. In humans, it is
the most abundant protein involved in the blood coagulation cascade and
circulates at concentrations ranging between 1-3 g/L.22, 23 The activated form of
fibrinogen, fibrin, is the fundamental fabric of blood clots, holding all the
components of the clot together. Fibrin polymerization results in a meshy network
that provides an adhesive surface for platelets and traps red blood cells to form
the hemeostatic plug.1 Fibrinogen also provides an interacting and binding
surface for other components required for the formation of a stable clot and
subsequent clot degradation/fibrinolysis.22,

23

To understand the functions of

fibrinogen in the blood coagulation process, it is important to explore its unique
structural features.

Fibrinogen Structure
Fibrinogen is a 340kDa glycoprotein that contains two sets of Aα (67kDa), Bβ
(56kDa) and γ (47kDa) chains held together by 29 disulfide bonds.22, 24, 25 Each
fibrinogen molecule is a dimer arranged into a unique globular structure with four
major regions, which include a central E region, a helical coiled-coil region, the
distal D region, and the αC region (Figure 3).24, 26 The central E region consists of
the N-termini of each of the Aα, Bβ, and γ chains. The N-termini of the Aα and Bβ
chains contain fibrinopeptides A (FpA) and fibrinopeptides B (FpB), respectively.
The helical coiled-coil region is an extension of all three chains from the central E
region to the distal D regions.24, 27
9

Figure 3: Crystal Structure of Fibrinogen (PDB: 3GHG) showing the central E region and two distal D
domains. Two Aα chains (green and yellow), Bβ (cyan and orange) and γ chains (pink and grey) are also
shown to demonstrate the assembly of the dimer.

The D regions, composed mainly of the C-termini of the β and γ chains, flank
the ends of the fibrinogen molecule and contain an anchoring site utilized during
fibrin polymerization (Figure 3).18, 27 A majority of the C-terminal portion of the Aα
chain exists as a very flexible region known as the αC region (221-610) (Figure
4).28 The αC region is further divided into a more flexible N-terminal αC connector
(221-391) and a more compact C-terminal αC domain (392-610).28-30 The
intrinsic disordered nature of the αC region has made it difficult to identify from Xray crystallography studies of the fibrinogen molecule. Nonetheless, this region
has been proposed to play several roles during the assembly of the fibrin
network. The structural representation of the αC region is shown in Figure 4.

10

Figure 4: Structure of Fibrinogen. Representative structural features of fibrinogen showing central E, distal
D and αC regions (adapted from ref 27)

Prior to fibrin polymerization, the αC region is tethered to the central E
region.30,

31

Fibrinogen is converted to active fibrin upon thrombin cleavage of

fibrinopeptides A and B, on the Aα and Bβ chains respectively. Cleavage of
fibrinopeptides A and B initiates fibrin polymerization by exposing knobs “a” and
“b” in the central E region which interact with the complementary holes “A” and
“B” in the D region of another fibrin molecule.18 The αC region is also released
from the central E region following cleavage of fibrinopeptides A and B, making
this region available to participate in fibrin polymerization (Figure 5).18 Although
the αC region has been proposed to play important roles in fibrin polymerization,
little structural information is available on this region.
Recent approaches, including atomic force microscopy (AFM) and nuclear
magnetic resonance (NMR) spectroscopy, have been used to explore the
structural features of the αC region that contributes to its functional roles.31,

32

NMR spectroscopy experiments have demonstrated that a majority of the αC
11

region is intrinsically disordered. Meanwhile, recent AFM studies provided a
visual representation of this flexible αC region in the full-length fibrinogen,
highlighting its role in the lateral aggregation of protofibrils.31

Fibrinogen Function

Figure 5: Fibrin Polymerization illustrated (adapted from ref 30)

Fibrinogen provides an interacting surface for enzymes, proteases, and
inhibitors involved in the blood coagulation process. The αC region of fibrinogen
is a particularly attractive region for these interactions as shown by multiple
research studies. The plasmin inhibitor, alpha-2-antiplasmin, binds to the αC
region of fibrinogen and has been shown to be specifically crosslinked to K303 in
the αC region.33,

34

Alpha-2-antiplasmin’s inhibitory activity prevents the

premature degradation of clots.
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During the early stages of blood coagulation, thrombin cleaves fibrinopeptides
A and B from the central E region. Cleavage of fibrinopeptides A and B converts
fibrinogen (AαBβγ)2 to active fibrin (αβγ)2, releases the αC region, and exposes
knobs “a” and “b in the E region which have complementary binding pockets in
the D regions. Hydrophobic knob-hole interaction sets the foundation for the
formation of a soft clot made up of staggered protofibrils (Figure 5).35
The carrier B subunit of Factor XIII relies on fibrinogen as an interacting
surface to bring the catalytic A subunit of Factor XIII in close proximity to its
substrate for the transamidation (crosslinking) reaction.19 A proper structural
assembly of fibrinogen is necessary for its function and other components
involved in the blood coagulation cascade that rely on fibrinogen for the formation
of a stable clot. Fibrin is also the primary substrate for Factor XIII.25 Although
fibrin polymerization can proceed after activation of fibrinogen, a hard clot is only
formed in the presence of FXIIIa – a transglutaminase.28,

36, 37

Factor XIII

introduces γγ, αα, αγ, crosslinks between the α and γ chains of fibrinogen.38

39

A

clot that is more stable and resistant to degradation is formed as a result of this
crosslinking reaction.40, 41

The Transglutaminase Factor XIII
Transglutaminases (TGases) are a group of enzymes that catalyze
calcium and thiol-dependent post-translational protein modifications. These
enzymes are best known for their role in blood coagulation, skin barrier formation
and extracellular matrix formation due to their ability to create stable lysis13

resistant networks via inter and intra molecular crosslinks. The catalytic actions
of TGase involve transamidation, esterification, and hydrolysis reactions.42, 43
Factor XIII is the only member of the transglutaminase family that exists
as a dimer in its inactive zymogen form. In plasma, Factor XIII exists as a
320kDa tetrameric molecule (Factor XIII A2B2), with two enzymatic A-subunits
(~83kDa) and two carriers B-subunits (~80kDa).11,

42, 44

In plasma Factor XIII

A2B2, the B-subunits of Factor XIII have been proposed to play a protective role,
preventing the degradation and premature activation of the catalytic A-subunit.

19

Cellular Factor XIII is found in platelets and placenta, and is only composed of
the catalytic A-subunits (Factor XIII A2).42 Deficiencies in Factor XIII have been
associated with severe bleeding diathesis. Mutations affecting the catalytic Asubunit of Factor XIII have been shown to be more severe.45 In the absence of
the carrier B-subunits, the levels of Factor XIII A2 in circulation were lowered but
did not produce a drastic an effect as that observed in the Factor XIII A2 knockout
mice.46 In circulation, the carrier B-subunits have also been shown to play an
important role in positioning the catalytic A-subunit in an ideal location for
crosslinking through its interactions with Fibrinogen.43 The crystal structure of the
Factor XIII A2B2 has not been resolved. The structural features involved in the
interaction between Factor XIII A2 and B2 subunits are still unclear. However,
structural information on the catalytic A subunit has been successful in
understanding of this transglutaminase.44, 47
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Factor XIII Structure
Structurally, each catalytic A-subunit of Factor XIII (Factor XIIIA) contains
an activation peptide, a β-sandwich domain, a catalytic core, and two C-terminal
β-barrel domains (β-barrel 1 and β-barrel 2) as shown in Figure 6.44, 48 During the
activation of Factor XIII in plasma, the carrier B-subunits dissociate from the
catalytic A-subunits following thrombin cleavage of the activation peptide and
upon calcium binding. 19

Figure 6: Structure of the catalytic A subunit of Factor XIII (PDB: 4KTY).
Adopted from references 44 and 48

The catalytic core of Factor XIII consists of a Cysteine, Histidine, and
Aspartate triad, also conserved in all catalytic transglutaminases.49,

50

In the

presence of thrombin, the activation peptide is cleaved off the A-subunit to form
the active enzyme FXIIIa.40 Three calcium-binding sites have been shown to
exist on Factor XIII.44 In the presence of calcium, Factor XIII A adopts a suitable
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conformation required for activity.50 Factor XIII A can also be activated nonproteolytically in the presence of high millimolar calcium concentrations. Although
the concentrations required for this non-proteolytic activation are significantly
higher than physiological levels of calcium, cellular Factor XIII has been
proposed to be activated non-proteolytically by calcium. A recent study by Klebe
et al., crystal structures of Factor XIII A using an inhibitor in the active site and
high calcium concentrations (40 mM) suggest that the β-barrels are moved away
from the core structure to expose the active site (Figure 7).44 However, additional
research is needed to understand this mode of activation of Factor XIII including
its transition from an inactive dimeric to an active monomeric form.

Figure 7: Non-proteolytic activation of Factor XIII in the presence of high calcium concentrations
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Factor XIII Function
In blood coagulation, activated Factor XIII (Factor XIIIa) is known to
crosslink specific reactive glutamines within fibrinogen to lysines to form γglutamyl-ε-lysyl covalent isopeptide bonds.19,

51

Hydrolysis results in the

deamidation of glutamine to form glutamate. Esterification is more common in
other transglutaminases whereby the side chains of glutamines can be modified
by addition of fatty acids.42 Fewer reports of esterification have been shown with
Factor XIII. Strikingly, each transglutaminase has a unique specificity towards
reactive glutamines. Factor XIII’s selectivity for reactive glutamines is more
specific than lysines.52, 53 However, Factor XIII’s specificity towards one reactive
glutamines over another is still unclear.
During catalysis, activated Factor XIIIa selects a specific glutamine
containing substrate to serve as the first acyl acceptor (Figure 8). In addition to
the catalytic triad Cys 314, His 373 and Asp 396, a conserved tryptophan
(Trp279) has been shown to serve as an essential stabilizer employed during the
transamidation reaction.13,

50, 54

The γ-carboxyamide group on the reactive

glutamine reacts with cysteine to form the acyl enzyme intermediate γglutamylthioester with the release of ammonia. This is the rate-limiting step.54
The second substrate lysine, attacks and cleaves the thioester bond in a
deacylation step. The crosslinked γ-glutamyl-ε-lysyl product is then released
(Figure 8).
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Figure 8: Proposed Reaction Mechanism for Factor XIII transamidation reaction
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Factor XIII Crosslinks Reactive Glutamines in Fibrinogen

Figure 9: Transamidation reaction between reactive glutamine (red) and lysine (blue) by the activated
Factor XIIIa

Reactive glutamines in the γ and α chains of fibrinogen are the primary
physiological substrates of Factor XIIIa.55-57 Two reactive glutamines in the γchain (Q398 and Q399) have been identified as substrates of Factor XIIIa. By
contrast, multiple reactive glutamines in the α chains (Q221, Q223, Q328, Q366)
have been shown to be crosslinked by Factor XIIIa. Factor XIII’s ability to form, γα dimers and α-α polymers promotes lateral aggregation between fibrin
monomers resulting in a tighter fibrin network and a hard clot.4, 37, 58 Both γ-γ and
α-α crosslinks contribute separately to unique clot properties.59 Factor XIIIa also
crosslinks several clot-stabilizing proteins which protect the clot from plasminmediated degradation e.g alpha-2-antiplasmin and plasmin activator inhibitor 1
(PAI1).40, 60
Crosslinking by Factor XIII plays an important role in the overall nature of
the clot, altering clot properties to variable extents. In the absence of Factor XIII,
fibrin fibers have been shown to have thicker fibers.37,

61

Meanwhile in the

presence of Factor XIII, crosslinking results in thinner fibers, with increased fiber
compaction, and a less porous clot.62 Factor XIII crosslinking is suggested to
produce a tighter fibrin network through chain oligomerization in protofibrils,
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which in turn affects the rates of diffusion of fibrinolytic enzymes through the
fibrin clot network. Understanding the nature of Factor XIII crosslinking is
therefore needed to design specific Factor XIII inhibitors to alter clot properties to
different extents.

Cardiovascular Relevance and Significance of Research
Fibrinogen levels are currently used as a risk factor for cardiovascular
disease.63, 64 There is increasing evidence suggesting that the nature of the fibrin
clot plays an important role in thrombosis.18, 22, 59 Fibrinogen is the most abundant
component involved in blood coagulation with plasma concentrations ranging
from 1 to 3 mg/mL in plasma. Consequently, blood clots are composed of red
blood cells trapped in tight fibrin networks. Fibrin has a higher concentration in
clots than circulation and is the major components in all thrombi (venous or
arterial). Fibrin is therefore an ideal target for detecting and characterizing
thrombosis, particularly because of its high specificity and sensitivity in all
thrombi. The fibrin network also provides binding platforms for several clotstabilizing factors (e.g alpha-2-antiplasmin and factor XIII), which either enables
or prevent clot lysis.65 Factor XIIIa, for example, introduces fibrin-fibrin intra and
intermolecular covalent bonds within the fibrin network. Factor XIII also crosslinks
other substrates to fibrin that, renders blood clots more resistant to fibrinolysis.11,
66

Deficiencies in fibrinogen and Factor XIII have been identified across the

world. Most cases are presented with abnormal clot properties and especially
recurring miscarriages in women with certain fibrinogen and Factor XIII
20

deficiencies.22, 45 Interestingly, a majority of substrates responsible for resistance
in clot degradation are crosslinked to the flexible αC region of fibrinogen.58
Several mutations associated with disease have also been found in this region,
making it a candidate for deciphering the fibrin network at a molecular level.

Role of the αC region Fibrinogen
In recent years, studies have emerged exploring the αC region as a potential
biomarker in several pathological conditions.67 Previous studies have shown
several truncations and mutations in the αC region associated with bleeding
disorders.58,

68

Examples involving specific reactive glutamines include

Fibrinogen Otago, Fibrinogen Keokuk and Fibrinogen Seoul II.68-70 Fibrinogen
Otago (Aα 270) was discovered in a patient with mild bleeding and recurrent
miscarriages. Here, removal of about 60% of the C-terminus of αC region (Aα
271-610) resulted in abnormal clotting conditions, decreased circulating
fibrinogen, and a reduced rate of polymerization.71 In Fibrinogen Keokuk, a point
mutation at Gln328 into a stop codon results in a 46% truncation of the αC
region.69 This mutation and truncation resulted in abnormal bleeding conditions
and multiple miscarriages in two patients. In Fibrinogen Seoul II, a single
mutation in the reactive glutamine Gln328 to a proline results in impaired fibrin
crosslinking in a patient diagnosed with myocardial infarction.68 A recent study by
Duval et al, isolated the contributions of fibrin α and γ crosslinking. These
findings suggest that crosslinking from the alpha chain are responsible for fiber
stiffness and clot stiffness.59 It is therefore important to fully characterize the
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selectivity for each reactive glutamines to understand how Factor XIIIa
recognizes this intrinsically disordered αC region as a substrate. Most studies
have made use of physiological assays to understand patterns and trends
involved in dysfibrinogenemia. However, in depth evaluation of each crosslinking
glutamine has not been explored. The goal of this dissertation is to understand
crosslinking in the αC region of fibrinogen by ranking each reactive glutamine
and to use this information to elucidate Factor XIIIa’s substrate specificity. The
knowledge gained from this study can be used to develop new diagnostic tools
and therapeutic strategies to alter the nature of clots.

Structural features of the αC region
The αC region (221-610) makes up two thirds of the alpha chain of
fibrinogen. The intrinsically disordered nature of this region is promoted by a
large number of serines (17.7%) glycines (14.8%) and prolines (6.9%).

Figure 10: Amino acid sequence of Fibrinogen αC region (221-610). Five reactive glutamines (red)
crosslinked by Factor XIII and two Cysteine residues (bold) located C-terminal highlihted

QLQKVPPEWK
GSETESPRNP
TWKPGSSGPG
WNPGSSERGS
SGNARPNNPD
KELRTGKEKV
KEVVTSEDGS
FDTASTGKTF
SSSHHPGIAE
SYKMADEAGS

ALTDMPQMRM
SSAGSWNSGS
STGSWNSGSS
AGHWTSESSV
WGTFEEVSGN
TSGSTTTTRR
DCPEAMDLGT
PGFFSPMLGE
FPSRGKSSSY
EADHEGTHST

ELERPGGNEI
SGPGSTGNRN
GTGSTGNQNP
SGSTGQWHSE
VSPGTRREYH
SCSKTVTKTV
LSGIGTLDGF
FVSETESRGS
SKQFTSSTSY
KRGHAKSRPV
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TRGGSTSYGT
PGSSGTGGTA
GSPRPGSTGT
SGSFRPDSPG
TEKLVTSKGD
IGPDGHKEVT
RHRHPDEAAF
ESGIFTNTKE
NRGDSTFESK

The flexible αC connector (221-391) contains a majority of the reactive
glutamines crosslinked by Factor XIII. The αC domain (392-610) has more
structural features compared to the αC connector. Several truncations have been
explored to map these structural features in the αC domain. Medved et al.,
demonstrated that there are two anti-parallel beta chains within αC (406-483)
that form a β-hairpin. This is promoted by the presence of a disulfide bond,
Cys423-Cys453 in the αC domain.28
A segment of the αC region, Fibrinogen αC (233-425) previously shown to
bind to Factor XIII is explored in this dissertation. Factor XIII’s ability to crosslink
three reactive glutamines in this region was examined. This segment was also
used to explore any structural features located close to the Factor XIII’s binding
site (αC (389-402).
Hypothesis and scope of research
Intrinsically disordered regions of proteins have been increasingly
associated with diseases. In cardiovascular disease, the αC region of fibrinogen
would be one substrate to investigate and consider given that is the most flexible
region in fibrinogen. Research exploring fibrinogen deficiencies involving the αC
region already provide some evidence that this disordered region should be
explored extensively. Moreover, Factor XIII selects most reactive glutamines in
this region for crosslinking its substrates.26 Substrates of Factor XIII do not align
with any specific consensus sequences that demonstrate a preferred selectivity
for one reactive glutamine over another, on a particular sequence.42 We
hypothesize that Factor XIII’s substrate specificity in the αC region is not random
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but rather results from the flexible nature of this region and the presence of a
proximal binding site for Factor XIII. To test this hypothesis a combination of
mass spectrometry and NMR spectroscopy techniques were used.
A brief summary of these techniques and the detailed application for the
purpose of this study is discussed in Chapter 2. The first research goal to rank
the reactive glutamines in the αC region is discussed in Chapter 3. The role of a
previously proposed residue αCE396 on Factor XIII crosslinking ability is
explored in Chapter 4. In Chapter 5, initial structural studies to identify prestructured motifs in the αC connector region are discussed and future directions
for this research are presented in the concluding Chapter 6.
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CHAPTER 2
METHODS AND APPLICATIONS

Protein expression and purification of recombinant Fibrinogen αC (233-425)
The DNA encoding Fibrinogen αC (233-425) was obtained from Smith et
al. as a pGEX-6P-1 construct containing a GST-tag and a precision protease
recognition and cleavage site (Leu Glu Val Leu Phe Gln | Gly Pro). The
expression and purification steps were performed as previously described by
Smith et al. 72
Briefly, the DNA was transformed into BL21-Gold (DE3) E.coli. Starter
cultures were grown in 180 mL terrific broth (TB: 1.2% (w/v) tryptone, 2.4%
(w/v), 0.8% (w/v) glycerol), 20 mL phosphate buffer (171 mM KH2PO4, 942 mM
K2HPO4) and 200 µL ampicillin (100 mg/mL) and incubated at 37°C for 16 h in a
Brunswick Scientific shaker (Edison, NJ, USA) at 225 rpm. The starter culture
was used to inoculate a mixture of 1800 mL Terrific Broth, 200 mL phosphate
buffer and 2 mL 100 mg/mL ampicillin. Cell growth was monitored for OD600 0.70.9,

when

protein

expression

was

induced

by

adding

isopropyl-β-D-

thiogalactopyranoside (IPTG) to 1 mM. The cell culture was incubated with
shaking at 180 rpm for 16 h at 30°C in a Labline Incubator shaker. Cells were
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harvested by centrifugation (5500 rpm, for 10 min in a Beckman Coulter JA-10
rotor). The pellets were resuspended in 180 mL wash buffer (20 mM Tris acetate,
50 mM NaCl pH 8), and the resuspended cells were then pelleted by
centrifugation at 5000 rpm for 1 h at 4°C. The cell pellets were quick frozen at
and stored at -20°C.
Cells were lysed in the same manner as described Smith et al.72 Cells
were resuspended in 88 mL phosphate buffer saline (PBS: 137 mM NaCl, 2.7
mM KCl, 10 mM NaHPO4.2H2O, 2 mM K2HPO4 pH 7.4), incubated with 1 mg/ml
lysozyme, 1 mM dithiotreitol (DTT) for 30 min at 25°C. 4 mM Benzamidine, 2
µg/mL aprotinin, 1 µM pepstatin-A and 10 µM leupeptin were added to the
mixture and incubated for 30 min at 4°C with gentle stirring. After the addition of
phenylmethansulphonylfluoride (PMSF) to 0.5 mM and sodium deoxycholate to
0.05% (v/v), this mixture was incubated at 25°C for another 30 min. To this lysate
triton X-100 was added to 0.02% (v/v) with vigorous agitation. DNase I (to 5
µg/mL) and MgCl2 to 5 mM were added and the mixture incubated for 10 min at
4°C and quenched with the addition of ethylenediamine tetraacetic acid (EDTA)
to 6 mM and streptomycin (1 g). The cell lysate was then spun at 13,500 rpm for
20 min at 4°C. The soluble protein in the supernatant was filtered through 0.45
µm and then 0.2 µm vacuum filters (Nalgene), and purified with a GST- affinity
resin column (GE Healthcare) on an AKTAprime™ FPLC system (Amersham
Scientifics) (Figure 11).
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Figure 11: GST trap columns connected in series to optimize protein yield from 4 L culture. The bottom
column serves as an additional catch column during the protein elution step that traps any uncleaved
GST-tagged proteins thereby increasing protein purity

Fibrinogen αC (233-425) was cleaved off the GST-tag using a
PreScission™ Protease at 2 U per 100 ug protein as recommended by GE
Healthcare and eluted in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2
mM KH2PO4 pH 7.4) at room temperature. An additional GST-trap column was
used during the elution to ensure high protein purity (Figure 11). This catch
column traps any uncleaved GST-tagged protein during the elution step, thereby
increasing the protein purify of the αC (233-425) fractions collected.
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Figure 12: A representative SDS-PAGE gel (15%) of fractions with Fibrinogen αC (233-425)
eluted from GST-Trap column following on column cleavage (Lanes 1-8) shows protein band at 20kDa.
Fraction eluted with gluthathione (Lane 9) shows position of GST-tag (25 kDa) relative to protein fractions.
MW = molecular weight marker.

Complete cleavage of the GST tag from αC was confirmed by SDS –
PAGE (Figure 12). Fibrinogen αC (233-425) and GST have similar molecular
weights; SDS PAGE alone could not definitively distinguish between these two
bands. Western blot analysis was used to verify the presence of αC only and no
free GST or uncleaved αC-GST in the protein fractions collected after cleavage
by the PreScission™ Protease. SDS-PAGE gels were prepared for Western blot
transfer. Protein fractions and samples from the glutathione elution step were
loaded on the gel. Following separation, the gel was then subjected to Western
blotting using an anti-GST-HRP Conjugate (Amersham™, GE Healthcare). All
Western blot set-up components were equilibrated in Western Blot transfer buffer
(25 mM Tris, 192 mM glycine, and 20% methanol) for 10 min at room
temperature. The gel was equilibrated in the same buffer then sandwiched
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between two nitrocellulose membranes. Transfer was performed at 100 V and
run for 1 h at 4°C. The transfer nitrocellulose membrane was developed as
specified by the manufacturer. Non-specific binding was reduced by shaking the
nitrocellulose membrane overnight at room temperature in a blocking solution
containing 3% BSA in PBST buffer (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM
NaCl, 0.001% Tween-20). The membrane was washed with fresh PBST buffer
and transferred to a solution containing 6 µL anti-GST HRP conjugate in 25 µL
PBST which was shaken for 1 h and rinsed in PBST, before the bands were
developed using TMB blotting buffer. The membrane was quenched with water.
Images of all gels and blots were taken on a Biorad Image system (Figure 12 and
13). Although the anti-GST antibody was not highly specific, comparison of
samples containing GST-tagged proteins and SDS-PAGE analysis confirmed
that the GST-cleaved Fibrinogen αC (233-425) protein fractions were free of the
GST-tag.

Figure 13: Western Blot analysis of Fibrinogen αC (233425) protein fractions (Lane 2 and 3) and GST-tag
fractions (Lane 5 and 6). Anti-GST antibody shows no
bands in fractions containing purified proteins. Fraction
eluted with gluthathione (Lane 5 and 6) shows bands
containing GST-tag
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The purified recombinant Fibrinogen αC (233-425) was concentrated in a
Vivaspin 2 concentrator (Sartorius Stedim Biotech, Goettingen, Germany), and
the concentration was determined using A280nm determined with a Cary 100 Bio
UV-Vis Spectrophotometer (Varian) and an extinction coefficient of 41480 M-1cm1

, calculated from ExPASy (http://web.expasy.org/protparam). Protein yields of 6-

11 mg were obtained from 4 L cultures. Concentrated protein was aliquoted for
storage at 4°C. All proteins with point mutations were expressed as described
above. A similar expression protocol with slight modifications was also adopted
for 15N and 13C-enriched αC (233-425) as discussed in Chapter 5.

Mass Spectrometry
Recent advances in mass spectrometry have been motivated by the need
to analyze large quantities of complex samples, identify biomarkers for disease,
and develop assays with very low limits of detection. Several mass spectrometry
approaches specific for proteomics have been developed. Mass spectrometry
allows for the separation of complex molecular species by their mass-to-charge
ratio upon ionization. MALDI-TOF (Matrix Assisted Laser Desorption/IonizationTime Of Flight) mass spectrometry and LC-MS (Liquid chromatography - mass
spectrometry) approaches were used for experiments in this dissertation.
MALDI-TOF mass spectrometry is a matrix-assisted approach whereby
sample ionization is enabled by the transfer of energy from the matrix. The matrix
absorbs energy from the laser and transfers this energy to the sample that is
ionized. The ionized species are then accelerated via a voltage grid through a
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time of flight tube toward a detector with reflectron capabilities. Sample
preparation is a key step in mass spectrometric analysis, and in the case of
MALDI-TOF MS, the choice of matrix is also important. 73
Two general approaches are utilized in proteomics for sample preparation;
the “top-down approach” and the “bottom-up approach.” The top-down approach
explores proteins in their intact state whereas in the bottom-up approach,
proteins are digested and the data obtained can be pooled to characterize the
whole protein.74 For this study, the transamidation reaction catalyzed by Factor
XIII was monitored using the bottom-up approach. Here, peptide fragments
containing the reactive glutamines of interest were identified and monitored after
Chymotrypsin, and GluC digests. Two common matrices for peptide/protein
analysis, α-cyno-4-hydroxycinnamic acid (αCHCA) and ferulic acid matrices were
optimized and used for the chymotrypsin and GluC digests, respectively (Figure
14).
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Figure 14: Chymotrypsin and GluC digests of Fibrinogen αC (233-425) showing peaks containing all three
reactive glutamines (Q237, Q328, and Q366)

Chymotrypsin digest
2448 - NSGSSGTGSTGNQ328NPGSPRPGSTGTWNPGSSERGSAGHW

GluC Protease digest
1349 - SSVSGSTGQ366WHSE
1550 - GPLGSTDMPQ237MRME

MALDI-TOF MS on Fibrinogen αC (233-425)
To identify peaks containing reactive glutamines in Fibrinogen αC (233425), this sample was separately digested with chymotrypsin (1 h) and GluC
protease (2 h) at 25°C. Each sample was then zip-tipped using a C18 resin tip,
and α-cyano-4-hydroxycinnamic acid (αCHCA) and ferulic acid matrices were
used for chymotrypsin and GluC protease digests, respectively. A MALDI-TOF
mass spectrometer (Applied Biosystems Voyager DE-PRO) was employed to
analyze these samples. The spectra obtained were compared with theoretical
digests to identify peaks containing reactive glutamines.
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One peak containing Q328 was observed when αC (233-425) was
digested with chymotrypsin, and the two other reactive glutamines were
observed in peaks from the GluC digest. It should be noted that peaks containing
Q328 and Q366 were confirmed using the theoretical digest whereas Q237 was
identified using LC-MS/MS (Waters Synapt G2-Si). The peptide fragment with
Q237 was shown to have five extra residues (GPLGS) from the precision
protease cleavage site, which are not a part of the wild type αC sequence. Two
reactive glutamines, Q398 and Q399, on the Fibrinogen gamma module γ(148411) were also identified following a GluC digest. A summary of all peptide
fragments discussed here and in subsequent chapters is listed in Table 1.

33

Table 1: Summary of peptide fragments containing reactive glutamines, Q!N
mutations, and other important residues characterized by MALDI-TOF mass
spectrometry

Species

Peptide Fragment

Average
m/z

Q237

GPLGSTDMPQMRM

1550

GluC

Q237N

GPLGSTDMPNMRM

1535

GluC

Q328

NSGSSGTGSTGNQNPGPRPGSTGTW

2448

chymotrypsin

Q328N

NSGSSGTGSTGNNNPGPRPGSTGTW

2347

chymotrypsin

Q366

SSVSGSTGQWHSE

1349

GluC

Q366N

SSVSGSTGNWHSE

1334

GluC

SGSFRPDSPGSGNARPNNPDWGT
FEE
SGSFRPDSPGSGNARPNNPDWGT
FAE
GQQHHLGGAKQAGD

2776

GluC

2647

GluC

1501

GluC

E396
E396A
γ398
γ399

Digest

MALDI-TOF MS Kinetic Assay
This kinetic assay was adapted from a previously described work on FXIII
substrate specificity for Q-containing peptides substrates.48 The Q-containing
protein substrate was combined with the lysine mimic glycine ethyl ester (GEE) in
the presence of activated Factor XIII. At different time points, aliquots of the
reaction were quenched and peptide digests performed to monitor for fragments
containing reactive glutamines and its crosslinked product (Figure 15).
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Figure 15: Scheme for MALDI-TOF MS kinetic assay

MALDI-TOF MS Kinetic Assay on Fibrinogen αC (233-425)
The assay was prepared in a 1.5 mL centrifuge tube with a final volume of
250 µL. Recombinant FXIII (500 nM) was activated with bovine thrombin (8.4
U/mL) in the presence of CaCl2 (4 mM), glycine ethyl ester (GEE, 17 mM) and
buffer [100 mM Tris-acetate, 150 mM NaCl and 0.1% PEG, pH 7.4] for 10min at
37°C. Thrombin was inhibited with 200 nM PPACK (D-phenylalanyl-L-prolyl-Larginine chloromethyl ketone).
The transglutaminase reaction was initiated by adding Fibrinogen αC
(233-425) at a final concentration of 13.6 µM. 25 µL aliquots were removed at
various time points and quenched in EDTA (0.5 mM). 6 µL of each aliquot were
digested separately with chymotrypsin (1 h) or GluC protease (2 h). Each sample
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was zip-tipped using a C18 resin tip. Chymotrypsin and GluC samples were
analyzed with α-cyano-4-hydroxycinnamic acid (αCHCA) and ferulic acid
matrices respectively, using a MALDI-TOF mass spectrometer (Applied
Biosystems Voyager DE-PRO). The Factor XIII-mediated reaction between each
reactive glutamine with GEE results in an additional 86 m/z seen as a product
peak on each spectrum. A representative MALDI-TOF time course spectra
showing the reactant disappearing and product peak appearing is shown in
Figure 16.

Figure 16: Representative data showing reactant and product peak
formation at different time points from MALDI-TOF MS kinetic assay.

The peak height ratio method (see equation below) was used to determine
the extent to which Factor XIIIa incorporated GEE over time.
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∑ Reactant peak height
∑ Reactant peak height + ∑ Product peak height

* peptide concentration

MALDI-TOF MS Kinetic Assay on Fibrinogen Gamma Module γ (148-411)
The gamma chain of fibrinogen contains two reactive glutamines (Q398
and Q399) known to be crosslinked by Factor XIII. To test this MALDI-TOF MS
Kinetic Assay, a fibrinogen gamma module γ (148-411) sample was obtained
from the lab of Dr. Alisa Wolberg (UNC Chapel Hill). Using a GluC digest, a
peptide fragment containing both reactive glutamines Q398 and Q399 was
identified with a 1501 m/z (GQQHHLGGAKQAGD) (Table 1 and Figure 17). The
MALDI Kinetic Assay was tested using this gamma module as the Q-substrate.
After optimizing the assay for this new substrate, a higher concentration of Factor
XIII and longer reaction times were required to observe the crosslinking reaction
in the gamma module compared to the αC (233-425) segment. Two peaks
corresponding to one (1587 m/z) and two (1673 m/z) glycine ethyl esters
crosslinked to the reactive glutamines were observed by 30 min (Figure 17). The
peak containing one reactive glutamine showed increasing intensity at 60 and
120 min.
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Figure 17: MALDI TOF Kinetic Assay was also used to demonstrate
crosslinking in gamma module γ (148-411) of fibrinogen

Liquid Chromatography – Mass Spectrometry
This assay and sample preparation approach was also compatible with
the liquid chromatography-mass spectrometry (LC-MS). Liquid chromatography
provides an additional separation step with unique retention times for each
peptide fragment. When coupled with mass spectrometry, specific peptide
fragments of interest can then be identified by their mass-to-charge ratio. In this
project, the LC-MS method provided higher throughput and a more automated
approach than the MALDI-TOF MS to characterize the crosslinking reaction
between reactive glutamines in the αC region.
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LC-MS Experimental Approach
Sample Preparation
The crosslinking reaction was carried out in the same way as described
for the MALDI TOF MS kinetic assay. Samples obtained at each time point were
prepared for LC –MS analysis as summarized below. A volume of each sample
was diluted with three volumes of 2% v/v acetonitrile (ACN) / 0.1% v/v
trifluoracetic acid (TFA) to a final volume of 30 µL. A p10 ZipTip® was wetted
with 3 x 10 µL 80% v/v ACN / 0.1% v/v TFA, equilibrated with 3 x 10 µL 2% v/v
ACN / 0.1% v/v TFA, the sample was cycled in the tip 15 x 10µL, the tip was
washed with 4 x 10 µL 2% v/v ACN / 0.1% v/v TFA, and the sample was eluted
into 30 µL 80% v/v ACN / 0.1% v/v formic acid. The samples were frozen and
then dried in a SpeedVac. The dried samples were dissolved in 30 µL 2% v/v
ACN / 0.1% v/v formic acid and 4 µL of each sample were analyzed.
Liquid Chromatography
A 250 µm ID x 15 cm Radel R tube (Idex Health & Science LLC, Oak
Harbor, WA, USA) was packed in-house with Aeris Peptide 3.6 µm XB-C18
material (Phenomenex, Torrance, CA, USA).

2 µm stainless steel Frit-in-a-

Ferrule™ Super Flangeless™ PEEK fittings (Idex) were used to retain the
material at both ends of the column. An Acquity M-Class UPLC® system (Waters
Corporation, Milford, MA, USA) was used with buffer A (water with 0.1% v/v
formic acid) and buffer B (acetonitrile with 0.1% v/v formic acid) as mobile
phases. Following injection of the sample onto the column, separation was
accomplished with a 40 min linear gradient from 2% B to 40% B, followed by a 5
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min linear gradient from 40% B to 85% B, and a 5 min wash with 85% B. A Low
Flow Electron Spray Ionization (ESI) probe was used to introduce sample into a
ZSpray LockSpray source (Waters).

Mass Spectrometry
A Synapt G2-Si mass spectrometer (Waters) was used to collect data
from the LC eluate. An MSe Continuum method was created in MassLynx v4.1
SCN924 (Waters) operating in positive mode. A 1.5 s low energy continuum scan
without trap or transfer collision energy was acquired, followed by a 1.5 s high
energy continuum scan (15 to 40 V ramp trap collision energy; no transfer
collision energy). The scan range was 50 to 2000 Da for GluC-digested samples
and 50 to 3000Da for chymotrypsin-digested samples. Leucine enkephalin
(556.2771 Da/e) at 300 pg/µL in 1:1 acetonitrile: water was used as the lock
mass during data acquisition.

Data Analysis and Results
The precursors with the reactant and product peaks from +1, +2 and +3
charged states from both reactant and product peaks at each time point were
extracted using Skyline Lab Software. The Q-GEE modification was incorporated
into the search library for quantification. The peak height ratio method was also
used to characterize each reactive glutamine from the peaks detected in the LCMS assay. A comparison of the data obtained from the MALDI kinetic assay and
the LC-MS kinetic assay obtained in triplicate is shown in Figure 18. This data
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suggests that both MALDI-TOF MS and LC-MS approaches produce a similar
trend for each reactive glutamine.

Figure 18: Ranking reactive glutamines in Fibrinogen using (A) MALDITOF mass spectrometry versus (B) LC-MS approach
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This LC-MS approach provided a faster throughput, an improved detection
limit, and an efficient data analysis package to quickly monitor the crosslinking
reaction. The MALDI-TOF MS approach was employed to monitor crosslinking
trends for each reactive glutamine (Chapters 3 and 4). The LC-MS approach was
used to characterize each remaining glutamine following Q to N mutations of one
or more reactive glutamines (Chapter 4).

Nuclear Magnetic Resonance (NMR) Spectroscopy
In the absence of X-ray crystal structure information on proteins, twodimensional NMR can reveal through-space interactions of amino acid residues
within a protein. Several 2D experiments have been developed to obtain enough
information to elucidate structural characteristics of proteins.75 In fibrinogen, the
αC region is very flexible, and no crystal structure information is available for this
region. Previous studies have relied on NMR spectroscopy to obtain clues about
these structural features of the αC region.28,
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Similar strategies were adopted

for the current studies with Fibrinogen αC (233-425).

Heteronuclear Single Quantum Coherence Spectroscopy (HSQC)
In protein chemistry, two categories of two-dimensional (2D) NMR
experiments are generally employed –homonuclear and heteronuclear correlated
spectroscopy. Homonuclear experiments provide information about interactions
between the same nuclei (e.g proton-proton or carbon-carbon) and heteronuclear
experiments monitor spins from different nuclei (e.g proton-nitrogen and proton42

carbon). To produce magnetically sensitive nitrogen and carbon species, proteins
are typically enriched (100%) using [U-13C]glucose and [15N]ammonium chloride
to overcome low natural abundance levels for these nuclei species. Nonetheless,
sensitivities of both

13

C and

15

N are still significantly lower than the sensitivity of

protons (1H). 75, 76

Figure 19: Pulse sequence for a typical HSQC experiment. Each 90 and 180
degrees pulse applied is represented in the proton and nitrogen. The delay time
applied, τ = 1/4J and the time of evolution t shown. Polarization steps are shown
with the INEPT.

In 2D HSQC experiments, the intense spin polarization of the proton is
transferred to the heteronuclear spin (15N for example), through a series of pulse
sequences and a polarization step known as the INEPT (Insensitive Nuclei
Enhanced by Polarization Transfer). To increase the sensitivity further, the
polarization is transferred from the heteronuclear spin back to the proton for
detection by reverse INEPT.75, 77 A representation of the pulse sequence for the
HSQC experiment is shown in Figure 19. A typical 2D 1H-15N HSQC spectrum
consists of cross peaks at the chemical shifts of the 1H directly attached to an
15

N. Unique chemical environments provide distinct peak positions in both the

proton and nitrogen dimension (Figures 20 and 21). Compared to homonuclear
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experiments, heteronuclear experiments produce less spectral overlap for each
amino acid (i.e greater dispersion). In this dissertation, mainly heteronuclear
experiments were employed predominantly 1H-15N HSQC. A brief summary of
this approach is described below.

2D HSQC NMR experiment to monitor Factor XIII’s Crosslinking Reaction
The HSQC experiments complement the mass spectrometry assay data.
In the mass spectrometry assay, Factor XIII’s crosslinking ability is monitored by
the addition of 86 m/z to each peptide fragment containing a reactive glutamine.
An isotopically labeled substrate was used in the complementary 2D 1H-15N
HSQC NMR approach to produce a signal that would monitor the transamidation
reaction only. Factor XIII incorporates this labeled substrate into αC (233-425)
when crosslinked to each reactive glutamine 1 (Figure 20). The

15

N- labeled

glycine ethyl ester 2, [15N]GEE , is used for the 2D 1H-15N HSQC experiment.
[15N]GEE is covalent crosslinked to each reactive glutamine and is observed as a
single peak. In the 2D 1H-15N HSQC experiment, each peak corresponds to the
1

H attached to the

15

N upon crosslinking. The proton attached to the

15

N-labeled

nitrogen can be observed following the transamidation reaction. Due to the
unique chemical environment adopted upon crosslinking, only species involved in
the crosslinking reaction are observed. The unique chemical environment of each
reactive glutamine is also reflected in the spectra obtained from the 2D 1H-15N
HSQC experiment.
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Figure 20: Transamidation reaction catalyzed by Factor XIII monitored using a 2D 1H-15N HSQC NMR
approach. Factor XIIIa crosslinks 15N-labeled GEE to each reactive glutamine in Fibrinogen αC (233-425).
Three distinct peaks corresponding to the proton attached to the 15N appear upon crosslinking (Top Panel).
Mutation studies confirm the identity of each reactive glutamine (Q237, Q328, and Q366) crosslinked and
its unique chemical environment (Bottom Panels).

Figure 20 shows the reaction monitored in the complementary 2D 1H-15N
HSQC NMR experiment and results obtained from crosslinking the WT αC (233425) containing all three glutamines. The top right panel shows three peaks
corresponding to all three reactive glutamines crosslinked by Factor XIIIa. The
identity of each individual reactive glutamine was confirmed following point
mutations of two glutamines (Q) to asparagines (N) (Figure 20, Bottom panel).
Each peak appears in a unique position as a result of the chemical environment
surrounding these reactive glutamines.

45

The complementary NMR assay was also tested on the fibrinogen gamma
module γ(148-411). Two distinct peaks corresponding to two reactive glutamines,
Q398 and Q399, were observed (Figure 21). One peak was more intense than
the other suggesting that one of the reactive glutamines is crosslinked to a
greater extent than the other. Although these reactive glutamines are neighboring
identical residues (Q398, Q399), their HSQC crosspeaks do not overlap. The
ability to distinguish the surrounding chemical environments of these two
residues is an additional strength for the NMR approach. Future studies with
point mutations to one of the reactive glutamines will help to identify which peak
is crosslinked to a faster extent.

Figure 21: Complementary 2D HSQC NMR in fibrinogen gamma module (γ148-411). Two peaks
corresponding to two reactive glutamines Q398 and Q399 are observed in unique positions corresponding
to their chemical environments.
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Overall, the 2D 1H-15N HSQC experiments provide a direct method to
quickly monitor Factor XIII’s ability to crosslink reactive glutamines in fibrinogen.
The lower sensitivity of NMR experiments compared to mass spectrometry poses
a technical challenge. Higher protein concentrations are needed to observe these
peaks in the NMR assay compared to mass spectrometry.

2D HSQC NMR for Structural Characterization
In the second NMR approach, the entire backbone and side-chain
nitrogens in the protein were labeled to obtain global information about the
protein’s structure. Fibrinogen αC (233-425) was expressed in minimal media
containing [15N]ammonium chloride. 2D 1H-15N HSQC NMR experiments with this
labeled sample confirm that Fibrinogen αC (233-425) is mostly intrinsically
disordered (Figure 22). Intrinsically disordered proteins (IDPs) have a
characteristic 2D HSQC NMR profile with peaks clustered at 8-9 ppm in the
amide region.78 Although obtaining structural information from NMR studies is
typical, the intrinsically disordered nature of the αC region of Fibrinogen makes
this very challenging to achieve.
Fibrinogen αC (233-425), like most intrinsically disordered proteins,
contains a high percentage of prolines. Prolines do not have an amide proton
and are therefore not detected in the 2D HSQC experiments 1H-15N. To obtain
additional information for peak assignment, proteins are expressed with both
and

15

N labels. Fibrinogen αC (233-425) containing both

13

C and

15

13

C

N label was

expressed and purified. A combination of 2D and 3D experimental approaches to
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characterize the unique structural features for Fibrinogen αC (233-425) are
described in Chapter 5.

Figure 22: Representative backbone structure showing all labeled residues and the proline amide nitrogen
highlighted (Top Panel). 2D HSQC NMR spectra from 15N-labeled Fibrinogen αC (233-425) showing
characteristic profile for intrinsically disordered proteins
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CHAPTER 3
RANKING REACTIVE GLUTAMINES IN THE FIBRINOGEN αC REGION THAT
ARE TARGETED BY BLOOD COAGULANT FACTOR XIII

Introduction
Abnormal fibrinogen levels and fibrin clot structure have been associated
with

several

pathological

conditions

arteriosclerosis, and bleeding disorders.22,

including
35

cardiovascular

disease,

The N-termini of the fibrinogen

(AαBβγ)2 chains form the central E region, which extends via a coil-coiled region
to two terminal D regions. A flexible portion of the Aα chain—the αC region—
extends from the ends of the D regions and is tethered to the central E region.18,
29

To initiate fibrin polymerization, thrombin cleaves fibrinopeptides A and B from

the Aα and Bβ chains of fibrinogen to form fibrin monomers (αβγ)2.36,

39

These

cleavages lead to protofibril formation among fibrin monomers and also release
the αC region.26, 28, 29
At the final stage of blood coagulation, Factor XIIIa (FXIIIa) introduces γglutamyl-ε-lysyl isopeptide bonds between selective glutamines (Q) and lysines
(K) within fibrin to form a clot with enhanced elastic properties.11,

25, 37, 39, 40, 42

Moreover, the overall fibrin network has decreased fiber diameter, increased fiber
density, reports of thinner fibers, and increased clot stiffness.37, 59, 61, 62 FXIIIa first
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crosslinks fibrin γQ398 or γQ399 to fibrin γK406 thereby forming γ-γ dimers.
Crosslinks involving the fibrin α chain appear later and involve the generation of
α-α dimers, γ-α hybrids, and higher α-α polymers.55-57,

79

Five known reactive

glutamines in the αC region include Q221 (and/or 223), Q237, Q328, and
Q366.59,

80-82

FXIIIa also crosslinks α2-antiplasmin (α2AP), plasmin activator

inhibitor 2 (PAI-2), and fibronectin, into the fibrin clot network.21, 83-85 FXIII(a) and
fibrinogen play additional supporting roles in the presence of red blood cells
(RBC). FXIII binding to fibrinogen γ390-396 and subsequent crosslinking of the
alpha chain helps mediate RBC retention in venous thrombi.46, 86
The αC region of fibrinogen contributes its own critical roles in the assembly
and properties of clot structure.26,

31, 58, 87, 88

This region has also been directly

correlated with adhesion events.89-91 Fibrinogen αC region (221-610) is
composed of a flexible αC connector (221-391) and a more structured αC
domain (392-610).28, 29 During fibrin polymerization, crosslinking in the αC region
has been shown to promote lateral aggregation and protofibril staggering.26, 30, 31
Studies with native fibrinogen versus the mutant (γQ398N, γQ399N, αK406R)
have revealed independent contributions coming from α-α crosslinks.59,

92

Such

crosslinks play major roles in promoting clot stiffness, fiber straightening, and
hindering fibrinolysis.
Truncations to the αC region have been shown to alter the nature of the clot
formed.58 With Fibrinogen Otago, the Aα chain ends at P270 resulting in severe
hypofibrinogenemia. Further analysis revealed that loss of (271-610) leads to
impaired fibrin polymerization and the production of much thicker fibers.
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58, 70, 88

Fibrinogen Seoul II (Q328P mutation) exhibits impaired fibrin polymerization and
a reduced extent of α-α crosslinking due in part to loss of a reactive glutamine
within the αC region.68
Several studies have identified specific crosslinking sites in the αC region
responsible for lateral aggregation, but little is known about the individual reactive
glutamines and the roles played by the surrounding residues.55-57,

81, 82, 93, 94

Antibody studies by Procyk et al., identified a FXIIIa binding site within αC (242424) and then narrowed the site more specifically to αC (389-402).95 Using
recombinant αC (233-425), Smith et al demonstrated that the key contact region
for FXIII A2' (thrombin-activated) and A2B2 involves αC (371-425) with E396
playing an important role.41, 72 In close proximity to this FXIII binding region, αC
(233-425) contains three reactive glutamines (Q237, Q328, and Q366) that each
become crosslinked to a selective set of lysines within the fibrin clot network.57, 82
The aim of the current study was to characterize the glutamines within the
fibrinogen αC region (233-425) that are known to be crosslinked by FXIIIa under
physiological conditions. Matrix-assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry and 2D Heteronuclear Single Quantum
Coherence (HSQC) NMR assays were used to directly monitor FXIIIa-catalyzed
reactions between the substrate glutamines in αC (233-425) and a set of lysine
mimics.96 The results demonstrate that Q237 is the most reactive glutamine of
fibrinogen αC (233-425) followed by Q366 and Q328. Moreover, no glutamine is
dependent on another to react first in the series. New knowledge gained about
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these three glutamines is considered relative to the conformational features of
fibrinogen and to the mutants Fibrinogen Otago and Fibrinogen Seoul II.

Materials and methods
Proteins and chemicals
Human cellular FXIII was a generous gift from the late Dr. Paul Bishop. Stock
aliquots of FXIII were prepared in 18 MΩ deionized water and the concentration
measured on a Cary 100 Bio UV-Visible spectrophotometer using an extinction
coefficient of 1.49 (ml mg-1 cm

-1

) and stored at -70 ºC. Thrombin and glycine

ethyl ester (GEE) were obtained from Sigma Aldrich (St. Louis, MO). 15NH4Cl and
[15N]GEE were obtained from Cambridge Isotope Laboratories (Andover, MA).

Site-directed mutagenesis of αC (233-425) to generate Q to N substitutions
The PGEX-6P-1 plasmid vector contained cDNA for GST-tagged αC fragment
(233-425). This αC sequence was derived from the full-length fibrinogen Aα
chain cDNA.72 Individual glutamine substitutions, Q237N, Q328N, and Q366N,
were introduced into αC (233-425) using the QuikChangeII Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). The resulting
substitutions were confirmed with DNA sequencing. Plasmids encoding the
different αC (233-425) varients were transformed into BL21 Gold (DE3) E. coli
cells.
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Fibrinogen αC (233-425) expression
GST-αC (233-425) and its mutants were expressed as described previously
by Smith et al.72 with few modifications. Briefly, GST-αC expressing cells were
incubated in Terrific Broth (1.2% typtone, 2.4% yeast extract, 0.4% glycerol, 742
mM K2HPO4, 171 mM KH2PO4, and 0.1 mg/ml ampicillin) at 37°C on a rotary
shaker until the optical density at 600 nm reached 0.9. αC expression was
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) followed by
incubation at 30°C for 16 h. Cells were harvested by centrifugation at 5000 g at
4°C. Biomass was resuspended in Wash Buffer (20 mM Tris Base pH 8.0, 50
mM NaCl) and centrifuged at 5000 g at 4°C. Resulting pellets were stored at 20°C.
Frozen pellets were resuspended in phosphate buffer saline (PBS: 137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and incubated with
1 mM dithiothreitol and 1 mg/ml lysozyme, followed by the addition of 2 µg/ml
aprotinin, 1 µM pepstatin A, 10 µM leupeptin, 4 mM benzamidine hydrochloride,
0.5 mM phenylmethansulphonylfluoride (PMSF), 0.05% sodium deoxycholate,
0.02% triton X-100, 5 µg/ml Dnase I, and 5 mM MgCl. The Dnase I reaction was
quenched with 6 mM EDTA, and the lysate was centrifuged at 22,000 g at 4°C.
Supernatant was supplemented with 1% (w/v) streptomycin sulfate and
centrifuged at 22,000 g at 4°C.

The resulting soluble fraction was passed

through a 0.2 µm membrane filter and loaded on a GST-affinity column using an
AKTAprime™ system (Amersham Biosciences, Piscataway, NJ).
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An on-column procedure employing PreScission™ protease was used to
cleave αC (233-425) from the GST-tag. The released αC (233-425) was eluted
with PBS buffer. Complete cleavage of the GST tag was confirmed by SDS–
PAGE and Western blot analysis (Amersham™ anti-GST-HRP conjugate
antibody). The resultant αC (233-425) was concentrated in a 5,000 MWCO
Vivaspin 2 concentrator (Sartorius, Goettingen). Protein concentrations were
determined using an extinction coefficient of 41480 M-1cm-1 calculated from
ExPASy (www.expasy.org).

MALDI-TOF mass spectrometry kinetic assay: Monitoring crosslinking reaction of
glutamines in αC (233-425)
The ability of FXIIIa to crosslink each reactive glutamine in αC (233-425) to
the lysine mimic GEE was monitored using our previously optimized MALDI-TOF
mass spectrometry kinetic assay.48 Final concentrations of 500 nM FXIII, 17 mM
GEE, 4 mM CaCl2, and MALDI assay buffer [100 mM Tris-acetate, 150 mM NaCl
and 0.1% PEG8000 pH 7.4] were incubated at 37°C in a 1.5ml reaction tube. The
FXIII was activated with bovine thrombin (8.4 U/ml final) for 10 min and then 200
nM PPACK (D- phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) was added
to inhibit the thrombin. The crosslinking reaction between αC (233-425) and GEE
was initiated by adding a final concentration of 13.6 µM αC (233-425) to a total
assay volume of 250 µL. At different time points, a 25 µL aliquot of this reaction
mixture was removed and quenched in 1.6 µL of 160 mM EDTA (10 mM final).
Control experiments were performed in the absence of Factor XIII.
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All samples were subjected to proteolytic digestion with chymotrypsin and
GluC (Roche, Indianapolis, IN). For the digests, 6 µL of either the control or time
point sample were combined with 6 µL chymotrypsin buffer (100 mM Tris-HCl, 10
mM CaCl2 pH 7.4) and 1.5 µL chymotrypsin (1 µg/µL) and incubated for 1 h at
25°C. This digest was quenched with 2 µL 5% TFA. GluC digest was performed
in a similar manner with 6 µL of the sample, 6 µL GluC buffer (25 mM NH4HCO3
pH 7.8) and 1.5 µL GluC (0.05 µg/µL) incubated for 2 h at 25°C and quenched
with 5% TFA. All digested samples were zip-tipped and analyzed using a MALDITOF mass spectrometer (Applied Biosystems Voyager DE-PRO).48 α-Cyano-4hydroxycinnamic acid (αCHCA) matrix was employed for chymotrypsin digests
and ferulic acid matrix for GluC. This assay was done in triplicate using αC (233425) from three independent expression trials. The peak-height ratio method was
utilized to determine the extent of crosslinking of GEE to each reactive glutamine
with time. The amount of reactant left at each time was calculated as follows:
∑ Reactant Peak Height
∑ Reactant Peak Height + ∑ Product Peak Height

* Peptide concentration

15

N-HSQC NMR spectroscopy: Validating αC (233-425) crosslinking with

15

N-labeled substrates
FXIIIa-catalyzed crosslinking of

15

N-labeled NH4Cl or

glutamines in αC (233-425) was monitored using

15

15

N[GEE] to reactive

N- heteronuclear single

quantum coherence (HSQC) NMR spectroscopy.96 All assays were carried out in
a total volume of 400 µL with 10% D2O added for the NMR deuterium lock. Final
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concentrations are presented. For crosslinking reactions with

15

N[GEE], 800 nM

FXIII was proteolytically activated with 21 U/ml bovine thrombin in the presence
of 5 mM CaCl2 and 20 mM Borate buffer. Thrombin activity was quenched with
460 nM PPACK. 10 mM

15

N[GEE] and 35 µM αC (233-425) were added and

incubated for 1 h at 37°C. For the 15NH4Cl exchange reactions, 400 nM FXIII was
non-proteolytically activated in the presence of excess calcium (50 mM) and 20
mM borate buffer (pH 8) for 10 min at 37°C. Then, 100 mM

15

NH4Cl and 40 µM

αC (233-425) were added and the mixture was incubated for 1 h at 37°C. 10%
D2O was added and the mixtures transferred into Shigemi NMR tubes. All
reactions were analyzed at 25°C using a single z-axis gradient triple resonance
(HCN) cryoprobe run on a 700 MHz Varian Inova NMR spectrometer. The
parameters for the 1D HSQC were number of transients (nt) = 512, number of
increments (ni) = 1, number of points (np) = 2048, and sweep width (sw) =
7022.5. For the 2D HSQC, the parameters used were nt = 64, ni = 64, np = 2048
and sw = 7022.5. The spectra were processed using NMRPipe and nmrDraw.97

56

Results
Preparation and characterization of recombinant αC (233-425)
Recombinant αC (233-425) containing an N-terminal GST-tag and a
PreScissionTM protease cleavage site was overexpressed in E.coli and purified.
SDS-PAGE results and Western Blot analysis using an anti-GST antibody
confirmed that the absence of GST-αC and free GST protein in the αC samples.
The amino acid sequence of αC (233-425) can be found in Figure 23A.
MALDI-TOF mass spectral analysis of separate chymotrypsin and GluC
digests of αC (233-425) showed peptide fragments containing all three reactive
glutamines. Theoretical protease digests (Protein Prospector, UCSF) and MS/MS
analyses were used to identify the αC fragments. The chymotrypsin digest
exhibited a peak containing Q328 (2448 m/z) (Figure 23B) whereas the GluC
digest showed peaks for Q366 (1349 m/z) and for Q237 (1550 m/z) (Figure 23C).
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Figure 23: Proteolytic digests of fibrinogen αC (233-425) show three reactive glutamines in a MALDI-TOF
MS. (A) αC (233-425) sequence showing position of reactive glutamine in bold (B) MALDI- TOF MS
spectrum of αC (233-425) digested with chymotrypsin contained a fragment with one reactive glutamine
Q328 at 2448.7 m/z (C) GluC digest of αC (233-425) showed two peaks (1550.5 m/z and 1349.3 m/z)
containing Q366 and Q237, respectively in the MALDI-TOF MS

Monitoring crosslinking of Q237, Q328, and Q366 with GEE
Our MALDI-TOF mass spectrometry kinetic assay was used to monitor
FXIIIa-catalyzed crosslinking of each reactive αC (233-425) glutamine to the
lysine mimic GEE.

The crosslinking reaction was quenched at distinct time

points and then digested separately with appropriate protease. A representative
set of mass spectral data for a chymotrypsin (Figure 24A) and a protease GluC
digest (Figure 24B) show the reactant peak containing the Q of interest and the
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subsequent product peak (+ 86 m/z for the new Q-GEE). No reactions products
were observed in the absence of FXIIIa.

Figure 24: Crosslinking of reactive glutamines in fibrinogen αC (233-425) with lysine mimic glycine ethyl ester
(GEE). Representative MALDI-TOF spectra showing crosslinking reaction between reactive glutamine in αC
(233-425) and the lysine mimic GEE catalyzed by FXIIIa (A) Chymotrypsin digest at time points 0, 5, 10 and
15 min shows that the fragment peak containing reactive glutamine Q328 (2448.5 m/z) was crosslinked to GEE
by FXIIIa to form a product peak Q328-GEE (2534.5 m/z). Each spectrum was obtained from the same starting
assay and represents a quenched time point followed by a chymotrypsin digest analyzed using MALDI-TOF
MS (B) A similar plot with GluC digest at time points 0, 0.4, 5, and 10 mins shows reactant and product peaks
containing Q237 and Q366 and their respective GEE-crosslinked products (1636.5 m/z and 1434.3 m/z). Q237 is
mostly crosslinked to product by 20 seconds as compared to Q366, which was only crosslinked to product by 10
mins.
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The amount of reactant left after each time point was calculated using the
peak height ratio method. As shown in Figures 24B and 25, the peptide
containing Q237 was rapidly crosslinked by 20 seconds and completely depleted
by 5 minutes of reaction with GEE. FXIIIa was able to very effectively crosslink
the lysine mimic GEE to the Q237 side chain amine. Q328 and Q366 could also
undergo FXIII-catalyzed crosslinking with GEE but at a slower rate than Q237. A
plot displaying all three αC glutamines indicates that the order of reactivity toward
GEE crosslinking was Q237 >> Q366 ≈ Q328. Reactions with Q366 and Q328
could be brought closer to completion by increasing the FXIIIa concentration by
3-fold and the incubation time to 120 minutes (Figure 25B). When the original
FXIIIa concentration was reduced 15-fold, the Q237 reaction rate became much
slower with a 50% loss of reactant occurring by 5 minutes (data not shown).
There have been previous reports on FXIIIa-catalyzed crosslinking pairs that
involve α-chain glutamine residues and their respective lysine partners.

82, 94

Using the current assay strategy, the individual reactivities of each glutamine
could, for the first time, be directly monitored.
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Figure 25: Plot showing combined reactivities of Q237, Q328 and Q366 in fibrinogen αC (233-425)
(A) A combined graph showing the rate of consumption of all three reactive glutamines
Q237 (diamonds ♦), Q328 (squares ■), and Q366 (triangles ▲). The peak height ratio method was used to
calculate the amount of reactant left in triplicate experiments and plotted as mean ± STD. These reactive
glutamines were ranked as Q237 > > Q366 ≈ Q328. (B) An increase in FXIIIa concentration by 3-fold
shows that Q366 reacts comparably with Q328 even at higher time points.

2D

15

N HSQC NMR confirms that

15

N labeled substrates crosslink to reactive

glutamines
15

N-labeled substrates have been used to follow reactions and conformational

changes in proteins. Here, 2D HSQC NMR was used to further examine the
crosslinking of

15

N-labeled substrates (15N[GEE] and

glutamines on αC (233-425). With the

15

15

NH4Cl) to the reactive

N[GEE] reaction, the magnetically silent
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14

NH2 on the αC glutamine side chains was replaced with NMR active

15

NH

amide product that is part of the FXIIIa-catalyzed GEE dependent reaction
(Figure 26A). The 2D HSQC spectrum of the FXIIIa-catalyzed reaction shows
three crosspeaks with each peak corresponding to an amide 1H (8.4-8.1 ppm)
directly attached to a

15

N (114 ppm range) (Figure 26B). The observed HSQC

peaks revealed that FXIIIa had successfully crosslinked

15

N[GEE] into the three

reactive glutamines within αC (233-425). One crosspeak clearly had an intensity
greater than the other two (Figure 26B). Additional HSQC studies demonstrated
that 15NH4Cl could also be utilized as a lysine replacement (Appendix 3).
HSQC experiments with

15

N[GEE] were then carried out using αC (233-425)

mutants in which a single Q was replaced each time with a non-reactive N. As
shown in Figure 26C, each mutant displayed two as opposed to the three
crosspeaks seen in wild-type αC (233-425). A comparison of chemical shift
positions and the mutant employed revealed that the strong intensity peak at
(114 ppm, 8.35ppm) corresponds to the Q237. Q328 occurs at (113.8 ppm, 8.20
ppm) and Q366 at (113.9 ppm, 8.16 ppm) (Figure 26B and 26C). The high
intensity peak for Q237 matches well with the highest reactivity observed with the
MALDI-TOF mass spectrometry kinetics assay and followed by Q366 and Q328.
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Figure 26: Reactive glutamines in αC (233-425) are crosslinked by FXIIIa in wild-type αC and following
single Q to N substitutions (A) Reaction scheme for FXIIIa-catalyzed crosslinking reaction of 15N-GEE with
reactive glutamines in αC (233-425) as monitored by NMR spectroscopy. B) 2D 1H-15N HSQC NMR
spectrum for the reactions between αC (233-425) and 15N-GEE. The three NMR peaks observed correspond
to successful crosslinking reactions with the three glutamines Q237, Q328, and Q366. C) FXIIIa-catalyzed
reactions between 15N-GEE and the individual αC mutants Q237N, Q328N, and Q366N as monitored by 2D
1
H-15N HSQC NMR. In αC Q237N, peaks corresponding to Q328 and Q366 were seen (top). Q237 reacted
fastest following either Q328N or Q366N substitutions (middle and bottom panels).
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Discussion
Within a blood clot, FXIIIa introduces γ-glutamyl-ε-lysyl crosslinks between
specific reactive glutamines and lysines located in the fibrin γ and α chains.25, 40,
57, 93

Little is known about the individual contributions of each reactive glutamine

and how FXIII selects one glutamine over another. We characterized and ranked
three reactive glutamines in fibrinogen αC (233-425) for their abilities to be
crosslinked by FXIIIa to the lysine mimic GEE. MALDI-TOF mass spectrometry
and NMR strategies were employed that would allow us to directly measure
individual reactivities.
Several studies have demonstrated that FXIIIa first introduces γ-γ crosslinks
into the blood clot followed by α-α crosslinks.61, 79 Putative binding sites for FXIIIa
have been identified within α and γ fibrinogen chains, and such sites are located
either upstream or downstream from the crosslinking glutamines.46,

72

γ-γ

crosslinking plays key roles in fiber appearance time and the generation of fiber
density whereas α-α crosslinking is a major determinant in fibrin clot stiffness and
hindering fibrinolysis ability.38,

59

Interestingly, there are far more covalent Q-K

pairs involving the α chains than the γ.82 FXIIIa crosslinks fibrin γQ398 or γQ399
to γK406.79 By contrast, the αC region contains multiple reactive glutamines
[Q221 (and/or Q223), Q237, Q328, and Q366] and multiple reactive lysines
[K418, K448, K508, K539, K556, K563, K580, and K601].81, 82, 93
Curiously, there is no obvious consensus sequence for the Q-containing
substrates of FXIIIa.52,

98, 99

The reactive glutamines are often found in flexible

regions of the substrates. It is important to point out that not all freely available
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glutamines are good FXIII substrates.

Fibronectin contains three glutamines

toward its N-terminus but only Q3 is highly reactive, minor crosslinking involves
Q7 and Q9.85 α2-Antiplasmin (N1) contains two reactive glutamines near the Nterminus but only Q2 is utilized. Reactive glutamines of α2-antiplasmin and PAI-2
become crosslinked to reactive lysines (K230, K303, and K413) within αC (233425).21 α2-Antiplasmin is one of the few FXIIIa substrates that can be studied
employing short peptides. Sequences based on α2- antiplasmin (N1, 1-15) have
been used to characterize individual glutamines, evaluate roles of surrounding
residues, and assess effects of peptide length.60, 100, 101 By contrast, similar sized
peptides based on the fibrinogen Aα and γ chains make poor Q-substrates for
FXIIIa.102, 103 These observations suggest that fibrinogen chains require a larger,
more protein-like environment to promote substrate specificity.
αC (233-425), containing close to 200 amino acids, has been shown to be
a highly promising system for probing the FXIIIa substrate specificity toward the
Aα chain.41, 72 αC (233-425) has three reactive glutamines and a putative FXIIIa
binding site. GEE serves successfully as a lysine mimic and targets
physiological, reactive glutamines.56, 60, 103 Unlike spectrophotometric assays that
indirectly monitor crosslinking activity or SDS PAGE gels that provide more
general conclusions about crosslinking, our mass spectrometry kinetic assay
directly follows each reactive glutamine. By focusing on αC (233-425), the
challenges of working with multiple competing glutamines and lysines both on
fibrinogen Aα and γ chains were also avoided.
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Using the MALDI-TOF mass spectrometry assay, we were able, for the first
time, to rank the individual glutamine players in fibrinogen αC (233-425). Results
revealed that Q237 was the most reactive followed by Q366 and Q328. Our
complementary NMR techniques validated these findings. Interestingly, the αC
region is mostly disordered and no X-ray crystallographic information is available.
Despite this disordered nature, all three glutamines in αC (233-425) could still
serve as FXIIIa substrates. Other FXIIIa substrates may take advantage of even
more defined structural features. Fibronectin, α2-antiplasmin, and PAI-2 each
contain a flexible region for the reactive glutamine(s) that is further supported by
a folded protein architecture. Unlike Aα based peptides, we propose that the
larger αC (233-425) exhibits some localized conformational environment that
allows or promotes interactions with FXIIIa.
The αC reactivity ranking Q237 >> Q366 ≈ Q328 provides new information to
help interpret crosslinking pairs reported recently for full length fibrinogen.82 For
that study, the FXIIIa catalyzed crosslinking reactions were followed by trypsin
digests and mass spectral analysis. Wang demonstrated that Q237 could be
crosslinked to more lysine pairs (αK418, αK508, αK539 αK556 and αK601) than
all other reactive glutamines that were probed.82 The high reactivity documented
for Q237 suggests that this amino acid is well positioned to crosslink a variety of
reactive lysines. Unlike Q237, Wang reported that αC Q366 only crosslinks to
K539. It should be noted that Q328 was not identified in Wang’s study. Previous
investigations, however, have shown that Q328 is an important reactive
glutamine.68,
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In this assay, we were able to characterize Q328 following a
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chymotrypsin digest. The ability to monitor all three reactive glutamines
simultaneously in αC (233-425) is enhanced by digesting each sample time point
separately with chymotrypsin and Glu C (Figure 23).
Using an NMR assay, we were able to confirm that FXIIIa crosslinks both
[15N]GEE and

15

NH4Cl to reactive glutamines (Figure 26 and Appendix 3) in a

similar order as seen in the MALDI-TOF kinetic assay. Furthermore, FXIIIa still
crosslinks Q237 fastest following Q328N or Q366N mutations (Figure 26). Also
in the absence of the most reactive glutamine Q237N, both Q328 and Q366 are
shown to be crosslinked to GEE by FXIIIa (Figure 26). Thus, FXIIIa does not
need to crosslink the fast acting αC Q237 before moving on to the other reactive
glutamines. Further mutant combinations reveal that if any of the three Qs is
replaced with a nonreactive N, the other two Qs can still participate in the
crosslinking reactions (Figure 26). The data collected thus far suggest there is
no obvious sequentiality in FXIIIa crosslinking.
Our current results can also be considered relative to disease-associated
fibrinogen truncations and mutants. In Fibrinogen Otago, a major portion of the
αC region (271-610) is absent and in Fibrinogen Keokuk, a single point mutation
changes Q328 to a stop codon generating a larger truncation.69, 70 In both cases,
Q221, Q223, and Q237 are still available for crosslinking by FXIIIa but Q328,
Q366, and multiple reactive lysines are missing. Our MS assay suggests that
Q237 is highly reactive and the Wang studies revealed that this glutamine
interacts with several lysines. FXIIIa may catalyze a heterodimeric reaction
between fibrin αC Q237 and fibrin γK406.
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In normal fibrinogen, the α-γ

heterodimer has been reported to make up 2% of the fibrin crosslink
contributions, but the reactive Q and K partners have not been identified.104 αC
Q237 (and/or Q221, Q223) might therefore help support the dominant fibrin γ-γ
crosslinks observed in SDS-PAGE gels of Fibrinogen Otago treated with FXIIIa
and calcium.68
In Fibrinogen Seoul II, a single point mutation results in αC Q328 being
replaced with proline (Q328P). With this mutation, fibrin γ-γ crosslinking occurs
but α-α is impaired.68 Considering our data, Q237 and Q366 would still be
available in the Seoul II patients along with potential K residues in the more Cterminal portion of αC. Multiple crosslinks involving highly reactive Q237 may,
however, not be sufficient to overcome the introduction of Q328P.
Recombinant variants that model Fibrinogen Seoul II revealed that
Q328P/Q366P exhibited greater impairment of fibrin polymerization than the
single mutants Q328P or Q366P.71 The current work with αC (233-425) suggests
Q328 and Q366 exhibit similar reactivities. With each single P substitution, the
pyrrole group may induce a conformational change that hinders fibrin architecture
and subsequent crosslinking. A greater disruption occurs with the double mutant.
Fibrin α-α crosslinking, however, was still observed and likely involved Q237,
Q221, and/or Q223. Unlike working with Q328P and Q366P, Q to N substitutions
within αC (233-425) provides a more conservative strategy for understanding the
contributions of the different reactive Q residues. Moreover, any glutamines still
present within αC mutants can be individually monitored and kinetically ranked.
Q237 always remained the most reactive glutamine but no obvious sequentiality
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in FXIIIa crosslinking was observed. Park and coworkers propose that
conformational problems resulting from P328 help explain the consequences of
Seoul II. Another possibility to consider is that crosslinks containing Q328 (and/or
Q366) play structural roles within the fibrin clot that differ from those of Q237,
Q221, and Q233. These issues can be further probed in the future using fulllength fibrinogens.
In summary, we have characterized and ranked three known reactive
glutamines Q237, Q328, and Q366 in fibrinogen αC (233-425) using a MALDITOF mass spectrometry kinetics assay and a complementary 2D HSQC NMR
approach. αC Q237 was shown to be the most reactive glutamine followed by
Q366 and Q328. Moreover, FXIIIa can independently crosslink these reactive
glutamines. Additional studies will help better understand the individual crosslinking contributions from each reactive Q and their unique effects on clot
properties. Continuing investigations on the αC region are anticipated to provide
new clues about sources of FXIII substrate specificity and their applications in
future drug or assay substrate designs.1

1

This chapter is reproduced in part from the published manuscript: Mouapi, K.

N., Bell, J. D., Smith, K. A., Ariens, R. A., Philippou, H., and Maurer, M. C. (2016)
Ranking reactive glutamines in the fibrinogen alphaC region that are targeted by
blood coagulant factor XIII, Blood 127, 2241-2248.
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CHAPTER 4

INVESTIGATING THE ROLE OF KEY MUTATIONS IN FIBRINOGEN αC (233425) IN CONTROLLING FACTOR XIII’S ABILITY TO CROSSLINK REACTIVE
GLUTAMINES (Q237, Q328, Q366)

Introduction
In the blood coagulation cascade, three proteins—fibrinogen, Factor XIII
and thrombin—play important roles at the end of the cascade to form a stable
clot that is resistant to fibrinolysis.18 The most abundant of these three clotting
factors is fibrinogen. Fibrinogen has been shown to play multiple roles in the
clotting process.23, 39 First, the fibrin forms a meshy network at the site of injury
and is important in the formation of the haemostatic plug.1 Fibrinogen also
provides a suitable surface for binding several components required for the
stability of a clot including platelets and antifibrinolytic enzymes.34,

105

Recent

studies have emphasized the role of the αC region of fibrinogen in promoting
several functions of the fibrinogen molecule.59, 86, 87
Duval et al. showed that Factor XIII-catalyzed crosslinking reactions
involving the αC region provided unique contributions to the overall clot stability.
Fibrin α-chain crosslinking resulted in increased fiber thickness and tautness and
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decreased fibrin clot lysis rate.59 Crosslinking in the αC region was found to
increase clot stiffness to a greater extent than crosslinking in the γ chain. Byrnes
et al. also demonstrated that in the absence of the αC region, red blood cell
retention in the fibrin clot is decreased.86 Together, these studies confirm the
unique functional contributions of the αC region of fibrinogen. Few reports have
elucidated the relationship between Factor XIII’s ability to bind to the αC region
and the role of the binding site in promoting Factor XIII’s crosslinking activity.
Previous studies by Credo et al. showed that activation of plasma Factor
XIII A2B2 was enhanced by a segment on the αC region, αC (242 - 424).106, 107
Procyk et al. later localized the placental Factor XIII A2 binding site on fibrinogen
to αC (389-402) using antibodies specific for segments of the Aα, Bβ, and γ
chains of fibrinogen. Of all the antibodies monitored, the anti-Aα 389-402 was
shown to significantly decrease Factor XIII’s ability to bind to fibrinogen
suggesting that the binding site for Factor XIII was located within this region.95
Using Surface Plasmon Resonance (SPR), Smith et al. and showed that plasma
Factor XIII A2B2 binds tighter than Factor XIII A2 to Fibrinogen αC (233-425).
Smith et al. also demonstrated that αC (389-402), with the sequence
(PDWGTFEEVSGNVS), is highly conserved across different species.72 Residue
E396 (highlighted in bold above) is located within this binding site and was
proposed to promote Factor XIII’s binding interaction with fibrinogen. Smith et al.
later showed that a synthetic peptide (Pep1-PDWGTFEEVSGNVS) containing
E396 and the surrounding amino acids derived from αC (389-402) substantially
inhibited Factor XIII’s binding interaction with αC and delayed crosslinking
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activity. Other synthetic peptide segments that were derived from Pep1
containing the αC E396A mutation and scrambled amino acids did not result in
the same inhibitory effect.41 Together, these previous findings suggest that E396
and other surrounding residues promote Factor XIII’s ability to bind to the
fibrinogen molecule. Although Factor XIII binding was significantly reduced in the
Fibrinogen αC E396A, it remains unclear whether this reduction also alters
Factor XIII’s ability to crosslink each reactive glutamine.
In the previous chapter, crosslinking of individual reactive glutamines
Q237, Q328, and Q366 in Fibrinogen αC (233-425) were characterized and
ranked using a combination of mass spectrometry and NMR spectroscopy
assays. Our results suggested that the reactive glutamines are crosslinked to
different extents, now ranked as Q237 >> Q366 ≈ Q328.108 This ranking aligns
with the number of glutamine–lysine crosslinking pairs identified by Wang et al. in
full-length fibrinogen.82 Q237 was shown to be involved in more lysine
crosslinking pairs than either Q366 or Q328. In this chapter, the MALDI kinetic
assay used to further characterize the role of a critical αC residue, E396, located
within the binding site of Factor XIII. A combination of mass spectrometry and
NMR was used to monitor crosslinking of each reactive glutamine in the
presence of the E396A mutation within Fibrinogen αC (233-425). Our findings
suggest that in the presence of Fibrinogen αC (233-425) E396A, Factor XIII can
still crosslinks all three reactive glutamines to similar extents as compared to
Fibrinogen αC (233-425) WT. This effect was the same whether recombinant
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Factor XIII A2 or plasma Factor XIII A2B2 were used in the presence or absence
αC E396A.
To further probe the role of each individual reactive glutamine, mutations
Q237N, Q237N/Q328N, and Q237N/Q366N were introduced into WT αC (233425) and crosslinking patterns involving the remaining Q328 and Q366 residues
were monitored. These two reactive glutamines are located upstream from the
Factor XIII binding site αC (389-402) and were previously modeled to experience
the most effect in the presence of Pep1.41 For this study, the mass spectrometry
kinetic assay was further optimized for use on a Waters Synapt LC – MS system
for higher throughput. Reactive glutamines, Q328 and Q366, were monitored
individually and in the presence of the Q237N mutation. Studies with Q237N
showed that Q366 is crosslinked to different extents in the absence of one or
more reactive glutamines.
Materials and Methods
Proteins and Materials
Factor XIII A2 was a generous donation from the late Dr. Paul Bishop.
Factor XIII A2B2 was purchased from Enzymes Research Laboratories. Thrombin,
glycine ethyl ester and other assay components were purchased from Sigma
Aldrich. 15N-labeled glycine ethyl ester was purchased from Cambridge Isotopes.
Fibrinogen αC (233-425) WT (Fbg αC WT) was expressed and purified as
described in Chapter 2. To insert an E396A mutation into this fibrinogen
segment, a single nucleotide base change was required. The codon GAG for
E396 was mutated to GCG to code for alanine (A396). The following primers
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were

designed

for

this

purpose,

CTGGGGCACATTTGAAGCGGTGAGGAAATG-3ʹ

and

Forward
Reverse

5ʹ5ʹ-

CATTTCCTGACACCGCTTCAAATGTGCCCCAGTCTGG- 3ʹ. The QuikChange II
site-directed mutagenesis kit was used to insert this mutation using the WT
cDNA as the template. The E396A point mutation was confirmed by DNA
sequencing. This DNA was then transformed into BL21-Gold(DE3) E.coli cells,
expressed, and purified under the same conditions as the WT Fbg αC (233-425).
For simplicity, Fibrinogen αC (233-425) expressed with E396A is referred in this
chapter as Fbg αC E396A. Other variants of Fibrinogen αC (233-425) used in
this

Chapter

include:

Q237N,

Q237N/Q366N

(or

“Q328

only”),

and

Q237N/Q328N (or “Q366 only”). The primers employed to introduce these Q to N
substitutions are listed in Appendix 1. All variants of Fbg αC (233-425) were
expressed and purified using a GST affinity trap column and on-column cleavage
using human rhinovirus 3C protease with a GST tag. SDS PAGE and Western
Blots were used to confirm the purity of protein fractions collected. Protein yields
in the 3-6 mg/L range were obtained. When necessary, protein fractions were
concentrated in a 5000 MWCO Vivaspin 2 concentrators. Protein concentrations
were determined using the absorbance at 280 nm and an extinction coefficient of
41480 M-1cm-1. The presence of each mutation in the protein was confirmed by
analyzing proteolytic digests (GluC or chymotrypsin) of protein fractions using
MALDI-TOF mass spectrometry.
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2D 1H-15N HSQC NMR Assay
To test the ability of Factor XIIIa to crosslink all three reactive glutamines
in Fbg αC E396A, the 2D HSQC NMR experiment was performed as previously
described in Chapter 2. Briefly, Factor XIII A2 was activated by incubating 800
nM Factor XIII with thrombin (21 U/mL) and CaCl2 (5 mM) for 10 min at 37˚C.
Thrombin was quenched using 200 nM PPACK. The crosslinking reaction was
initiated by adding the lysine mimic

15

N-labeled glycine ethyl ester (10 mM

[15N]GEE) and Fbg αC E396A (40 µM) to activated Factor XIII. The total assay
volume was 400 µL in 20 mM borate buffer (pH 8). This reaction mixture was
incubated for 30 min at 37˚C. D2O (10%) was added to the sample for the NMR
deuterium lock and then transferred to a Shigemi NMR tube.
This reaction was analyzed using a Varian Inova 700 MHz NMR
spectrometer at 25˚C with a single z-axis gradient triple resonance (HCN)
cryoprobe. The following parameters were used to obtain the 2D HSQC results;
nt = 64, ni = 64, np = 2048 and sw = 7022.5. The spectrum was processed using
NMRpipe and nmrDraw.

MALDI- TOF mass spectrometry kinetic assay
The previously described MALDI –TOF mass spectrometry kinetic assay
was used to monitor the Factor XIIIa-catalyzed crosslinking reaction between
reactive glutamines in Fbg αC (233-425) and the lysine mimic GEE (Chapter 2).
This assay allowed us to compare crosslinking of each reactive glutamine in Fbg
αC WT versus E396A. The assay was performed as described previously with a
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few modifications. Factor XIII A2 or Factor XIII A2B2 (500 nM) was incubated in
the presence of GEE (17 mM) and Fbg αC WT or E396A (13.6 µM final
concentration) for 5 min at 37˚C in MALDI Kinetic buffer (100 mM Tris acetate,
150 mM NaCl and 0.1% PEG8000 pH 7.4). To activate Factor XIII A2 or Factor XIII
A2B2 and thereby initiate the reaction, thrombin (8.4 U/ml) and CaCl2 (4 mM)
were added to the reaction mixture. At different time points, 25 µL aliquots from
this reaction were removed and quenched in 1.6 µL of 160 mM EDTA (10 mM).
Samples from this reaction were digested separately with Chymotrypsin and
GluC and analyzed on the MALDI TOF Voyager DE/Pro mass spectrometer as
previously described in Chapter 2. The peak height ratio method was used to
analyze and compare crosslinking in Fbg αC WT versus E396A.

Liquid chromatography- mass spectrometry (LC-MS) kinetic assay
Our previous NMR HSQC studies (Chapter 3) suggested that reactive
glutamines can be crosslinked in the absence of one or more of these
glutamines. In this initial study, one or more reactive glutamines (Q) where
mutated into an inactive asparagine (N) residue. An LC-MS analysis approach
was used to monitor crosslinking in Fbg αC (233-425) with the following Q
mutations: Q237N, Q237N/Q366N, and Q237N/Q328N. Factor XIII’s ability to
crosslink Q328 and Q366 in these variants was compared with Fbg αC WT. The
kinetic assay was performed in the same manner as described for the MALDI
TOF MS assay above. Final concentrations of Factor XIII A2 and Fbg αC (233425) WT and its variants were maintained at 500 nM and 13.6 µM, respectively.
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Aliquots quenched from different time points were digested separately with
Chymotrypsin and GluC and analyzed using an LC-MS approach described
below.
Digested samples were prepared as follows for analysis on the LC-MS
system. A P10 ZipTip® with 0.6 µL of C18 resin (Merck Millipore Corp., Billerica,
MA, USA) was used to prepare the samples. One volume of each sample was
diluted with three volumes of 2% v/v acetonitrile (ACN) / 0.1% v/v trifluoracetic
acid (TFA) to a final volume of 30 µL. A ZipTip® was wetted with 3 x 10 µL 80%
v/v ACN / 0.1% v/v TFA, equilibrated with 3 x 10 µL 2% v/v ACN / 0.1% v/v TFA,
the sample was cycled in the tip 15 x 10 µL, the tip was washed with 4 x 10 µL
2% v/v ACN / 0.1% v/v TFA, and the sample was eluted into 30 µL 80% v/v ACN
/ 0.1% v/v formic acid. The samples were frozen and then dried in a SpeedVac.
The dried samples were dissolved in 30 µL 2% v/v ACN / 0.1% v/v formic acid
and 4 µL of each sample were analyzed.
A 250 µm ID x 15 cm Radel R tube (Idex Health & Science LLC, Oak
Harbor, WA, USA) was packed in-house with Aeris Peptide 3.6µm XB-C18
material (Phenomenex, Torrance, CA, USA).

An Acquity M-Class UPLC®

system (Waters Corporation, Milford, MA, USA) was used with buffer A = water
with 0.1% v/v formic acid and buffer B = acetonitrile with 0.1% v/v formic acid as
mobile phases. Following injection of the sample onto the column, separation
was accomplished with a 40min linear gradient from 2% B to 40% B, followed by
a 5min linear gradient from 40% B to 85% B, and then a 5-minute wash with 85%
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B. A Low Flow Electron Spray Ionization (ESI) probe (Waters) was used to
introduce sample to a ZSpray LockSpray source (Waters).
A Synapt G2-Si mass spectrometer (Waters) was used to collect data
from the LC eluate. An MSe Continuum method was created in MassLynx v4.1
SCN924 (Waters). The spectrometer was operated in positive resolution mode.
A 1.5 sec low energy continuum scan without trap or transfer collision energy
was acquired, followed by a 1.5 sec high energy continuum scan (15 to 40V
ramp trap collision energy; no transfer collision energy). The scan range was 50
to 2000Da for GluC-digested samples and 50 to 3000 Da for chymotrypsindigested samples. Leucine enkephalin (556.2771 Da/e) at 300 pg/µL in 1:1
acetonitrile : water was used as the lock mass during data acquisition. Skyline
data analysis software was used to obtain precursor ions for each reactant peak
and product peak species. The peak height ratio method was used to evaluate
the extent of crosslinking of each reactive glutamine over time.

Results
Factor XIIIa crosslinks all three reactive glutamines in Fibrinogen αC (233-425)
E396A.
A previously employed 2D 1H -15N HSQC NMR assay was used to monitor
Factor XIII’s ability to crosslink all three reactive glutamines in Fbg αC E396A.
The three reactive glutamines (Q237, Q328, and Q366) in αC (233-425) are all
located N-terminal to the E396A mutation. The 2D 1H -15N HSQC NMR approach
serves as a direct method to quickly access whether the loss of the acidic E396
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residue in αC (233-425) hinders the reactivity of Factor XIII towards these three
glutamines. With this heteronuclear NMR method, a single peak for each reactive
glutamine that becomes crosslinked to [15N]GEE is expected. This peak
corresponds to the proton that is attached to the NMR active nitrogen (15N). In
the absence of crosslinking, no peaks should be observed.
Our results on Fbg αC E396A revealed three distinct peaks, with each 2D
crosspeak appearing at a similar 1H and

15

N chemical shift as observed with Fbg

αC WT. The individual reaction products involving Q237, Q328 and Q366 from
Fbg αC E396A are shown in Figure 27. The results suggest that the E396A
mutation does not affect Factor XIII’s ability to crosslink all three reactive
glutamines in Fibrinogen αC (233-425).

Although the E396A mutation was

previously shown to reduce binding for αC (389 - 403) to Factor XIII, this
mutation did not inhibit Factor XIII’s ability to crosslink the reactive glutamines
under the conditions employed in our assay. To monitor the crosslinking of each
reactive glutamine to GEE over time, the MALDI-TOF MS kinetic assay was
employed. With such an approach, more subtle differences in reactivities of the
three glutamines could be probed.

79

Figure 27: 2D HSQC NMR for E396A shows peaks three peaks corresponding to three reactive glutamines
Q237, Q328, and Q366 crosslinked by Factor XIIIa

MALDI- TOF mass spectrometry kinetic assay to monitor Q237
Amongst the three reactive glutamines in Fibrinogen αC (233-425), Q237 was
the most reactive glutamine using our MALDI-TOF MS kinetic assay. However
using this assay design, Q237 was completely crosslinked to lysine mimic GEE
within 10 minutes of the reaction. To address this issue, the assay was modified
for shorter time points. Factor XIII’s ability to crosslink GEE to the reactive
glutamine Q237 in Fbg αC WT versus Fbg αC E396A could now be better
compared. Under these solution conditions, the observed reactivities for Q328
and Q366 would be very weak.
In the previous assay design (Chapter 3), Factor XIII A2 was pre-activated
and the reaction was initiated by adding the glutamine substrate source Fbg αC
(233-425).108 For this assay, Factor XIII (500 nM final) was incubated with Fbg
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αC WT or E396A, GEE, and MALDI kinetic buffer for 5 min at 25ºC to promote
Factor XIII binding and interaction with the Fibrinogen αC substrate. The assay
reaction was then initiated by adding thrombin and calcium to activate Factor XIII.
This experimental strategy is referred to here as the in-assay activation
approach. The time points obtained were digested separately with Chymotrypsin
and GluC as described in Chapter 3. The peak height ratio method was used to
quantify the amount of reactant left with time from the reactant and product peaks
obtained using the MALDI -TOF mass spectrometer.
Results demonstrate that although Q237 was crosslinked following the
E396A mutation, the crosslinking activity appeared to be slightly slower (Figure
28). This assay was monitored every 2 minutes for WT and every minute for the
E396A variant for a total of 10 min. Although the reaction with E396A appeared
to be slower, this reaction was not substantially different from the WT. The
results obtained indicate that full crosslinking for Q237 still occurs within 10 min
for the Fbg αC E396A mutation (Figure 28).
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Figure 28: Reactive glutamine Q237 monitored at lower time points to compare crosslinking extents in WT
(red circles) versus E396A mutation (blue circles) in the presence of 500 nM Factor XIII A2. Experiments
performed in triplicate and reported as mean ± STD

Reactive glutamines Q328 and Q366 are crosslinked to similar extents in Fbg αC
(233-425) WT and E396A.
To examine the effect of Fbg αC E396A on the other two reactive glutamines
Q328 and Q366, a higher concentration of Factor XIII (2 µM) was used and
reactivities monitored over an hour. Factor XIII was incubated with all reaction
components using the in-assay activation approach described above. Thrombin
and calcium were added to initiate the reaction, and aliquots were quenched at
different time points during the course of the assay for comparisons between Fbg
αC WT and Fbg αC E396A.
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The results confirm that reactive glutamines Q328 and Q366, are
crosslinked in Fbg αC E396A with a similar ranking as in the WT. During the first
20 minutes of the reaction, the amount of reactant left from reactive glutamines
Q328 and Q366 in Fbg αC E396A appears to be slightly greater compared to the
WT (Figure 29). This effect indicates that under the same reaction conditions,
Factor XIII tends to crosslink reactive glutamines in Fbg αC E396A slightly slower
than the WT. It is possible that in the presence of the αC E396A mutation, Factor
XIII is not as well anchored to the binding site as observed with WT αC.
Nonetheless, the ability for Factor XIIIa to crosslink all reactive glutamines, with a
similar ranking to the WT, is still maintained following the αC E396A mutation. To
further investigate the role of this mutation in controlling Factor XIII’s activation
and subsequent crosslinking ability, this assay was performed with the plasma
Factor XIII A2B2.
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Figure 29: Comparing crosslinking for each reactive glutamine in WT versus E396A using 2µM Factor
XIII A2

MALDI –TOF Kinetic assay comparing crosslinking with Factor XIII A2B2 in Fbg
αC (233-425) WT and E396A.
The Factor XIII binding site within Fbg αC (389-402) exhibits a higher affinity for
Factor XIII A2B2 than Factor XIII A2.72 Moreover, this binding site has been
previously proposed to play an important role in the activation of Factor XIII
A2B2.106 The MALDI-TOF MS Kinetic assay was used to rank reactive glutamines
in Fbg αC WT versus E396A as zymogen Factor XIII A2B2 was converted to
activated Factor XIIIa. During this activation process, the regulatory Factor XIII B2
subunits are released, and the catalytic Factor XIII A2 is activated. The assay
was performed as described for Factor XIII A2. Factor XIII A2B2 (500 nM final)
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was incubated with Fbg αC (233-425) WT or E396A in the presence of MALDI
kinetic buffer and glycine ethyl ester (GEE) using the in-assay activation
approach. The reaction was initiated by adding calcium (4 mM) and thrombin (8.4
U/ml). Aliquots obtained at different time points were quenched and analyzed
using the MALDI-TOF mass spectrometry approach. To compare the extent of
crosslinking for the most reactive glutamine Q237, time points were collected
with one-minute intervals (Figure 30).

Figure 30: Monitoring Q237 crosslinking in Fibrinogen αC WT and
E396A in the presence of 500 nM Factor XIII A2B2

Results suggest that Q237 can be crosslinked to GEE in the presence of
Factor XIII A2B2 for both Fbg αC E396A and WT. Although the extent of
crosslinking was slightly reduced in Q237 with Fbg αC E396A, this difference
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was not significant when compared to the extent of crosslinking in the WT (Figure
30).
Reactive glutamines Q328 and Q366 were also monitored at higher time
points and the extent of crosslinking compared in Fbg αC WT and E396A.
Results from these experiments confirm that all three reactive glutamines can still
be crosslinked with a similar ranking when plasma Factor XIII A2B2 is used
(Figure 31). The presence of E396A does not affect the ranking of these reactive
glutamines. Again, the extent of crosslinking for each reactive glutamine is
slightly reduced in the E396A. However, this effect is not significantly different
from the extent of crosslinking observed in the Fbg αC WT.

Figure 31: Comparing all three reactive glutamines crosslinked by Factor XIII A2B2 (500
nM) in Fibrinogen αC WT and E396A
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Crosslinking trends in Q to N mutations differ slightly amongst reactive
glutamines
The complementary NMR assay confirmed that in the absence of one or
more reactive glutamines, following a Q to N mutation, Factor XIIIa is still able to
crosslink any remaining reactive glutamines (Chapter 2 and 3). To monitor for
differences in the extent of crosslinking for Fbg αC (233-425) containing one,
two, or the original three reactive glutamines, an LC-MS based assay was
employed. This LC-MS assay was adapted from the MALDI-TOF MS kinetic
assay. The earlier NMR experiments provided a quick method to confirm that
crosslinking occurred after a 30-minute incubation time for each Q to N species
(Chapter 3). The LC-MS approach would now permit a more in depth analysis of
the interplay of each individual reactive glutamine. Moreover, the LC -MS assay
allows us to better monitor low intensity peaks and provides a faster throughput.
For these experiments, the pre-activated Factor XIII activation strategy
described in Chapter 3 was used.108 Briefly, Factor XIII A2 (500 nM) was preactivated in the presence of thrombin (8.4 U/ml) and calcium (4 mM).
Crosslinking for each Q to N mutation was then monitored following separate
Chymotrypsin and/or GluC digests. The LC –MS parameters used are detailed in
Materials and Method Chapter 2. The retention times and m/z values observed
for each peptide fragment containing a reactive glutamine are summarized in
Table 2. The peak intensity for each precursor ion detected by the mass
spectrometer was determined using Skyline data analysis software, and the peak
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height ratio method was employed to compare the extent of crosslinking across
different Q to N mutations.
Table 2: Average retention times and m/z values for peptide fragments
containing reactive glutamines analyzed by LC-MS
Reactive
Glutamine
monitored
Q237

Average
retention time
(min)
19.4

m/z +1

m/z +2

m/z +3

1549.6807

775.3440

517.2318

Q237-GEE

22.1

1635.7175

818.3624

545.9107

Q328

12.7

2448.0770

1224.5422

816.6972

Q328-GEE

18.3

2534.1138

1267.5606

845.3761

Q366

9.7

1348.5764

674.7918

450.1970

Q366-GEE

13.5

1434.6132

717.8102

478.8759

In the absence of the most reactive glutamine Q237 (i.e Q237N), the
remaining reactive glutamines Q328 and Q366 were crosslinked to a similar but
slower extent than the WT (Figure 32). Crosslinking of the most reactive
glutamine Q237 may have a modest influence on the ability of Factor XIII to
crosslink the other two reactive glutamines Q328 and Q366. Overall, reactive
glutamines Q328 and Q366 experience the slowest extent of crosslinking in
Q237N of all the αC series (Figure 32 and Figure 33).
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Figure 32: Extent of crosslinking in each reactive glutamine changes in the presence or absence of other
reactive glutamines. Averages obtained from LC –MS assay

To further probe for differences in the extent of crosslinking to Q328 and
Q366, these reactive glutamines were monitored individually using the double
mutations Q237N/Q366N (“Q328 only”) and Q237N/Q328N (“Q366 only”).
Reactivities were compared for Q328 in Fbg αC WT (Q237, Q328, Q366),
Q237N (Q328 and Q366) and finally with Q237N/Q366N (“Q328 only”). Of all
three αC variants, Q328 was crosslinked the fastest with Fbg αC WT. By
contrast, Q328 was crosslinked the slowest with Fbg αC Q237N where Q328
competes with Q366 for the lysine mimic GEE. When Q328 only (i.e Fbg αC
Q237N/Q366N) was monitored, the extent of crosslinking was slow at the start of
the reaction. At higher time points, the extent of crosslinking became comparable
to the Fbg αC WT (Figure 32).
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Figure 33: Comparison of crosslinking trends for Q328 in WT and following Q to N mutations

The reactivities of Q366 in Fbg αC WT, Q237N, and Q237N/Q328N
(“Q366 only”) was also evaluated. Similar to Q328, the extent of crosslinking
involving Q366 was significantly reduced in the absence of the most reactive
glutamine Q237. Surprisingly, in the absence of the other two reactive glutamines
(“Q366 only”), the extent of crosslinking involving Q366 occurred more rapidly
over time (Figure 34). Intriguingly, at higher time points the reactivity of “Q366
only” became greater than Q366 in WT.
These studies suggest that the ability of Factor XIIIa to crosslink Q366 or
Q328 is affected by the αC variant employed. With Fbg αC WT, Q366 begins to
show greater reactivity than Q328 at higher time points. When Q237N is
removed, Q328 and Q366 both exhibit similar slower reactivities than with WT.
With the double Q to N mutation, “Q366 only” clearly exhibited greater reactivity
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than “Q328 only” (Figures 33 and 34). It remains unclear what features enhance
the crosslinking extent in Q366.

Figure 34: Comparison of crosslinking trends for Q366 in WT and following Q to N
mutations using LC -MS

Discussion
The αC region of fibrinogen has recently been shown to play several roles
in formation of a stable clot.83, 106, 109 Factor XIIIa-catalyzed crosslinking in the αC
region contributes to increased fiber thickness, increased tautness, and
decreased clot lysis rate.59 Factor XIII has been shown to crosslink several
reactive glutamines in this αC region compared to only two reactive glutamines in
the Fibrinogen gamma chain. In our previous study (Chapter 3), a mass
spectrometry and a complementary NMR spectroscopy assay were developed to
monitor and rank the extent of crosslinking for three known reactive glutamines
(Q237, Q366, and Q328) within a segment of the αC region (αC 233-425).108 Fbg
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αC (233-425) was previously used to localize and characterize a Factor XIII
binding site within the fibrinogen Aα chain.72 A residue within this αC region, Aα
E396, was identified to be critical for the binding of Factor XIII. To further probe
the role of E396, we introduced an E396A mutation in αC (233-425) and
monitored Factor XIII’s ability to crosslink the reactive glutamines located
upstream of its binding site αC (389-402).
Using

this

MALDI-TOF

mass

spectrometry

kinetic

assay

and

complementary NMR spectroscopy assay the presence of the E396A mutation in
αC (233-425) was confirmed and Factor XIIIa was shown to still crosslink all
three reactive glutamines. To ensure that Factor XIIIA was exposed to αC (233425) prior to activation, an in-assay activation approach was adopted for all
experiments comparing crosslinking in WT versus E396A. Compared to the preactivation approach where activated Factor XIIIa was added to αC (233-425), in
the in-assay activation approach, all components for Factor XIII activation were
added in the presence of αC (233-425). No significant differences were detected
in the ranking of reactive glutamines for the in-assay and pre-activated Factor
XIII. At 500 nM, Factor XIIIa, Q237 was crosslinked to a slightly slower extent in
E396A compared to WT at earlier time points. It is still unclear whether this delay
is a result of the E396A mutation hindering Factor XIII’s ability to bind properly on
this site.
A higher Factor XIII A2 concentration (2 µM) was used to monitor
crosslinking in Q328 and Q366 over a longer time. These two reactive
glutamines are located upstream of the Factor XIII binding region within Fbg αC
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(389-402) and could experience larger differences in crosslinking upon
introducing E396A. A molecular modeling study by Smith et al. predicted that the
synthetic peptide (Pep1- PDWGTFEEVSGNVS), derived from the αC (389-402)
binding residues, would bind on Factor XIII. The results from this modeling study
suggested that αC (389-402) binding directs Q366 to a position closer to the
Factor XIII active site compared to Q328.41 The present results showed that
although Q366 seemed to be crosslinked to a larger extent than Q328, the
presence of the E396A mutation does not significant affect the extent of
crosslinking. Together, our findings suggest that the binding interaction promoted
by the key amino acid E396 does not affect the ability of Factor XIII to perform its
catalytic role.
Previous studies using a synthetic peptide (Pep1) derived from the αC
binding site for Factor XIII showed that Pep1 delayed Factor XIII-catalyzed
crosslinking. Smith et al. proposed that this delay in crosslinking was a result of
Pep1’s inhibitory effect on a site associated with the Factor XIII activation peptide
(AP) cleft. Molecular modeling studies using Pep1 suggested that E396 forms a
salt bridge with Arg 158 on Factor XIII, which further emphasized the role of
E396 in anchoring Factor XIII to this binding site.41 Surface Plasmon Resonance
(SPR) studies demonstrated that non-activated Factor XIII A2B2 bound to αC
(233-425) with a Kd = 7.3 nM, meanwhile, thrombin cleaved FXIII A2B2 bound
with a Kd = 21 nM in the presence of calcium.72 The αC region has also been
proposed to promote activation of Factor XIII A2B2.106 To investigate the effect of
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E396 on Factor XIII’s activation and subsequent crosslinking, plasma Factor XIII
A2B2 containing the carrier B-subunits was used.
The results from thrombin-cleaved Factor XIII A2B2 in the presence of
calcium showed that the catalytic subunit of Factor XIII A can still crosslink all
three reactive glutamines to a similar extent and ranking in both WT and E396A
αC (233-425). This feature suggests that the activation of Factor XIIII A2B2 is not
affected by E396. Compared to recombinant Factor XIII A2, crosslinking in
plasma Factor XIIII A2B2 was modestly slower for all three reactive glutamines.
An SDS-PAGE gel analysis monitoring over time the activation of Factor XIII A in
recombinant Factor XIII A2 and Factor XIIII A2B2 showed that Factor XIII A2 was
completely activated within 5 minutes, but Factor XIIII A2B2 was activated fully
only by 15 min (Appendix 4). This delay could be as a result of the presence of
the carrier B-subunits. Nonetheless, activation did not affect the extent to which
each reactive glutamine was crosslinked in both WT and E396A in αC (233-425).
We propose that although Factor XIII uses E396 as an anchoring site for binding,
its catalytic activity does not depend on this residue alone. Other surrounding
residues within the αC (389-402) must contribute to the overall binding
interaction. A truncation of this region will provide more understanding on the role
of this region in Factor XIII’s catalytic activity.
In addition to crosslinking all three reactive glutamines in Fibrinogen αC
(233-425) WT, Factor XIIIa has been previously shown to crosslink each reactive
glutamine independently following Q to N substitutions of one or more reactive
glutamines (Chapter 2 and 3). In this study, changes in Factor XIIIa’s ability to
94

crosslink Q328 and Q366 were monitored using an LC-MS strategy. These
results demonstrate that Q366 is most affected by Q to N substitutions. In the
absence of Q237, both Q328 and Q366 are crosslinked the slowest compared to
WT. Surprisingly, when both reactive glutamines Q237 and Q328 are substituted
with inactive asparagines, Factor XIIIa crosslinks Q366 (Q366 only) to a greater
extent compared to WT. In “Q328 only”, the differences across these mutations
are not as apparent as in Q366. Previous molecular modeling studies proposed
that Q366 is positioned closer to the active site compared to Q328.41 Factor XIIIa
could therefore more readily recognize and crosslink Q366, in the absence of the
competing Q237, since Q366 is located closest to Factor XIII’s binding site on
Fbg αC (233-425). By contrast, the extent of crosslinking in WT, Q237N, and
“Q328 only” were slightly different for Q328. These results suggest that Q328 is
least affected following substitutions of other reactive glutamines. The central
location of Q328 within the Fbg αC (233-425) may contribute to this effect. Q237
is located N-terminus of αC (233-425), but Q366 is located closest to Factor XIII’s
binding site. Factor XIII may therefore use a combination of proximity to the
binding site and substrate accessibility to select its preferred substrate for
crosslinking.
Together our results suggest that Factor XIII uses a surrounding region
within the binding site to promote its crosslinking activity. Although E396A was
previously proposed to play an important role in Factor XIII’s binding activity, this
substitution does not affect the catalytic role of either recombinant Factor XIII A2
and plasma Factor XIII A2B2. More studies are needed to probe the role of αC
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(389-402) in controlling Factor XIII binding and/or catalytic activity. Fbg αC (233425) could be truncated to αC (233-388) thus removing the proposed Factor XIII
binding site. Alternatively, additional mutations could be introduced into the αC
(389-402) segment of αC (233-425).
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CHAPTER 5

STRUCTURAL CHARACTERIZATION OF FIBRINOGEN αC (233-425) USING
NMR SPECTROSCOPY

Introduction
Intrinsically disordered regions and proteins have been increasingly
associated with diseases including cancer, Alzheimer’s, and cardiovascular
disease.110,
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The αC region of fibrinogen is very flexible, and the N-terminal

connector behaves very similar to intrinsically disordered proteins (IDPs).
Truncations and mutations in this region have also been correlated with disease
conditions associated with IDPs.68,

70

Furthermore, many of the reactive

glutamines crosslinked by Factor XIIIa are located in loop and flexible regions.25
In Chapters 3 and 4, three reactive glutamines in Fibrinogen αC (233-425) were
ranked to understand Factor XIII’s ability to crosslink these reactive glutamines.
The role of a mutation, E396A, within Factor XIII’s binding site was also explored.
Recent studies have proposed and demonstrated that some IDPs have
Pre-Structured Motifs (PreSMos) known to have some degree of structure.112
Molecular Recognition Features (MoRFs)—short protein regions that undergo
disorder-to-order transitions upon interaction with binding partners—have also
been shown in IDPs.113 These types of structural features have been
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hypothesized to enhance substrate binding and activity in IDPs. Whether the αC
region undergoes structural changes upon binding Factor XIII is not known.
Thus, the intrinsically disordered nature of Fibrinogen αC (233-425) is explored in
this chapter and the presence of pre-structured motifs are investigated using
NMR spectroscopy.
Table 3: Amino acid composition of Fibrinogen αC (233-425)
Residue
Ala (A)
Arg (R)
Asn (N)
Asp (D)
Cys (C)
Gln (Q)
Glu (E)
Gly (G)
His (H)
Ile (I)
Leu (L)
Lys (K)
Met (M)
Phe (F)
Pro (P)
Ser (S)
Thr (T)
Trp (W)
Tyr (Y)
Val (V)

Number of residues in
expressed Fibrinogen αC
(233-425)
4
12
13
4
0
3
13
40
3
1
4
4
3
2
18
40
21
7
2
4
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Percent
Composition
2%
6.1%
6.6%
2%
0%
1.5%
6.6%
20.2%
1.5%
0.5%
2%
2%
1.5%
1%
9.1%
20.2%
10.6%
3.5%
1%
2%

Intrinsically disordered proteins are composed of a high percentage of
glycines, prolines, serines, and threonines. As shown in Table 3, these residues
make up 60% of the amino acid composition of Fibrinogen αC (233-425). A
previous NMR study using fragments of the αC connector proposed that this
region has residues with poly-proline type II (PxxP) propensity.114 An initial
screening of Fibrinogen αC (233-425) using two disorder predictors PrDOS and
PONDR115 predict that a majority of this sequence is intrinsically disordered
(Figure 35). Interestingly, residues surrounding reactive glutamine Q366 and
additional residues (DWGTE*E) that contain E396 (*E) within Factor XIII’s
binding region were predicted to have a more ordered propensity (Figure 35).
Those residues exhibiting increased ordered propensities could contain
PreSMos. Furthermore, the residues surrounding the Factor XIII binding site
within αC (233-425) could contain MoRFs for Factor XIII. For this chapter, the
intrinsically disordered nature of Fibrinogen αC (233-425) is explored and the
presence of PreSMos investigated using NMR spectroscopy. Initial 3D NMR
experiments for peak assignments were also examined.
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TDMPQMRMELERPGGNEITRGGSTSYGTGSETE
SPRNPSSAGSWNSGSSGPGSTGNRNPGSSGTGG
TATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPG
SPRPGSTGTWNPGSSERGSAGHWTSESSVSGST
GQWHSESGSFRPDSPGSGNARPNNPDWGTFEE
VSGNVSPGTRREYHTEKLVTSKGDKELRT

Figure 35: Fibrinogen αC (233-425) sequence highlighting the number of glycines (blue) and prolines
(mostly bold) and reactive glutamines (red). PONDR graphic representation of Fibrinogen αC (233-425)
shows residues with higher score and probability to be disordered and a few residues with some degree of
structural propensity (underlined in red and shown in graph). Residues from PrDOS are underlined in
black.

Methods
IPAP NMR Experiments
2D 1H-15N HSQC NMR experiments on the αC fragment were measured in
the absence and presence of Pf1 phage alignment. This was followed by IPAP
experiments, which were measured in the absence or presence of the alignment
media Pf1 phage.116,

117

Pf1 phage was purchased from ASLA biotech

(distributed by CEDARLANE) at 1 g/mL stored in a solution. 500 µL of the phage
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was obtained and centrifuged at 90,000rpm for 1 h at 4°C. The phage pellet
obtained was resuspended and washed twice in the same NMR buffer used for
the protein sample (20 mM K2HPO4, 150 mM NaCl, pH 6.5). After the washes,
15

N – labeled αC (233-425) at a concentration of 200 µM was added to the phage

pellet and then resuspended by vortexing. The final concentration of Pf1 phage in
the sample was diluted to concentrations between 25-31 mg/mL (v/v), following
manufacturers guidelines. 10% D2O was added to this sample and then carefully
transferred to a Shigemi NMR tube using a teflon tube attached to a pipette tip.
The following parameters were employed to obtain the representative HSQC
spectrum. Number of transients (nt) = 64, number of t1 increments (ni) = 64,
sweep width = 7022.5. IPAP experiments were measured using the 800 MHz
Varian Inova with a triple resonance probe and pulsed field triple axis gradient.
The data obtained from all experiments were processed using nmrPipe.97 These
experiments were performed with the help of T. Michael Sabo.

Improved Protein Expression for 15N and 15N / 13C labeled αC (233-425)
For structural characterization and backbone assignment of fibrinogen αC
(233-425), the protein was expressed in minimal media containing
13

15

NH4Cl and

C-glucose. The resultant αC (233-425) would thus be double labeled for

solution NMR experiments. Using a procedure adopted from a previous study, a
strategy to express high-yield labeled protein was optimized.118 For these
experiments, starter cultures were first grown in 40 mL LB Broth and then
transferred into a larger LB culture (2- 4L) until cell growth attained an OD of 0.7.
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Cells were then harvested by centrifuging at 5000 rpm. The cell pellets obtained
were washed and resuspended in minimal media (M9 salts, MgSO4, thiamine
HCl, and glucose).
For the next steps, a 4:1 ratio was used for protein expression; i.e, pellets
from each 4L culture in LB broth were used to inoculate 1L of minimal media
containing 0.25 g/L of

15

NH4Cl and/or 4 g/L

13

C-glucose. To boost cell growth,

Bioexpress cell growth media with U-15N or U-15N/U-13C (Cambridge Isotopes
Laboratories Inc, Andover, MA) respectively, was spiked into the media (500 µL
volume for each 500 mL minimal media). This media significantly improves the
yield of labeled protein. Cells grown in minimal media containing
15

15

NH4Cl or both

NH4Cl and 13C-glucose were harvested by centrifugation at 5000 rpm. The cells

were then resuspended in PBS buffer and lysed in the same manner as
unlabeled αC (233-425) (Chapter 2).
An alternative to this lysis method was sonication. The cell lysate was
centrifuged at 13500 rpm for 20 min. The soluble supernatant was collected and
then filtered through a 0.4 µm and then a 0.2 µm filter. This soluble supernatant
was loaded unto three 5-mL GST Trap columns connected in series. The bound
GST-αC was subjected to in-solution digestion with human rhinovirus 3C
protease to cleave the GST-tag. The released αC (233-425) was collected as
the flow-through from the GST-column, and SDS-PAGE was used to evaluate
the purity of each fraction (2 mL). All other GST-tagged components were eluted
using 20 mM glutathione and fractions collected.
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Fractions containing

15

N-labeled αC or doubly labeled

15

N/13C Fibrinogen

αC (233-425) were individually combined and concentrated to approximately 150
µM for 15N/13C Fibrinogen αC (233-425) and >200 µM for the 15N-labeled protein
using a vivaspin (Sartorious, MWCO 5000) concentrator. Initially, these
concentrator units were washed twice with deionized water, followed by two
washes with PBS (same buffer used for protein elution). The Fibrinogen αC (233425) containing samples were spun at 5500 rpm for 15-minute intervals, and the
concentration of the protein measured regularly. When a concentration of 200 µM
was attained, the protein samples were transferred into a dialysis cassette bag
(3500 MWCO) for buffer exchange. The protein was dialyzed into 20 mM
K2HPO4, 150 mM NaCl, pH 6.5. The concentration of the sample was measured
and

further

concentrated

as

needed

(150-360µM)

using

the

vivaspin

concentrator. For all NMR experiments, 10% D2O was added and the mixture
transferred to a Shigemi NMR tube.

Results and Discussion
Fibrinogen αC (233-425) was successfully expressed in minimal media
containing

15

NH4Cl, as described in Chapter 2. Initial 2D [1H,15N]-HSQC NMR

experiments confirmed that this region shows characteristic spectra for
intrinsically disordered proteins (Figure 36). Such a unique spectral profile is
characterized by the clustering of peaks within a narrow 1H chemical shift range
in the amide proton region. In more structured proteins, peaks in the amide
protein region are dispersed with 1H shifts between 6-9 ppm. As shown in Figure
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36, the 2D [1H,15N]-HSQC NMR spectra for Fibrinogen αC (233-425) exhibits
peaks clustered between 8.0-8.5 ppm. Peaks corresponding to the amide
nitrogen from the side chains for glutamines and asparagines are highlighted at
7-8 ppm (blue circle). This cluster contains the 3 reactive glutamines and 13
asparagines. The indole NH side chains from aromatic tryptophan residues are
typically seen as peaks in the 10 ppm range (Figure 36, gray circle).

Figure 36: 2D [1H,15N]-HSQC NMR spectra for 15N- labeled Fibrinogen αC (233-425).
Areas on spectrum containing side chains of tryptophan highlighted in gray circle (10
ppm) and regions with asparagine and glutamine side chain residues also shown (blue
circle 7-8 ppm)
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Residual Dipolar Coupling experiments with Fibrinogen αC (233-425)
Recent studies have shown improved NMR approaches to characterize
protein structure and their binding interactions with ligands. One approach is to
utilize residual dipolar couplings (RDC), which has been employed as a
complement to distance constraints obtained from the nuclear Overhauser effect
(nOe).119-122 Such RDC based projects have been successfully used to
characterize IDPs and other proteins.123, 124 The magnitude of the RDC depends
on the distance between the coupled nuclei, the orientations of the vector formed
by the two nuclei relative to the alignment tensor, and the amplitude of dynamics.
Weak alignment is achieved in solution NMR using liquid crystals, gels, phages
and bicelles.75 By contrast, dipolar couplings average to zero in isotropic
conditions due to all possible orientations of the vector being accessible during
the course of the measurements. An anisotropic condition e.g phages, bicelles,
gels is a requirement for RDC measurements in solution NMR.76,

125

In this

weakly orienting environment, NMR dipolar coupling are usually less than 100 Hz
in anisotropic conditions.126
RDCs are complementary to nOe’s in that they provide information about
the orientation of a molecule with both long range and short-range interactions.
Unlike nOe’s, which provide distance restraints between atoms, RDCs have
information about the angles formed by a vector connecting the two atoms within
a tensor axis system.75 Through space interactions that arise between any two
magnetically active nuclei are measured under isotropic and anisotropic
conditions using an 2D [1H,15N]-in-phase/anti-phase (IPAP) HSQC NMR
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approach which will be used to obtain RDCs (Figure 37).76 2D [1H,15N]-IPAP
HSQC experiments are modified HSQC experiments designed to record NMR
signals that allow observation of the residual dipolar coupling and separation
from J coupling. 127,128 The IPAP experiments are performed in the absence and
presence of the alignment media.119 The presence of alignment media provides
anisotropic conditions that result in a measureable dipolar coupling constant.121

Figure 37: In-phase and anti-phase (IPAP) HSQC experiment. Scheme illustrating two peaks
observed in an HSQC and its corresponding IPAP HSQC in-phase (dark peak) and anti-phase
(dotted) peaks. Peak separation with and without alignment media Pf1 phage, illustrated to
demonstrate the source of residual dipolar coupling constant DNH for example (right) (adapted
from reference 75)

For Fibrinogen αC(233-425), RDC measurements were carried out with
the goal of probing for PreSMos. To test the feasibility with IPAP experiments,
Pf1 phage was used as an alignment media in the presence of

15

N –labeled

Fibrinogen αC (233-425).129 Spectral splittings obtained in the presence and
absence of the Pf1 phage alignment was measured to determine residual dipolar
couplings, DNH (Figure 38). Negative DNH RDCs are found for segments in which
the NH vector is largely oriented perpendicular to the polypeptide chain. For
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example in extended conformations and loops DNH values are mainly negative.
Meanwhile, positive DNH values are found in alpha helical segments. 78, 125, 129
The 2D HQSC spectrum obtained for

15

N αC (233-425) in the presence of

alignment media Pf1 phage showed a spectral profile similar to that without Pf1
phage (Figure 38). Representative spectra collected In-Phase and Anti-phase in
the IPAP experiments are displayed in Figure 39. The sum of peaks from InPhase and Anti-phase experiments are shown as well as the spectra obtained
from the difference of these peaks (Figure 40). To obtain RDCs, resolved peaks
from the 2D HSQC experiments were assigned arbitrary numbers 1-164 using
NMRpipe. For each peak, the frequency in the sum and differences IPAP
experiments was obtained using NMRPipe and recorded. Spectral splittings were
recorded from the difference between a corresponding IPAP sum and IPAP
difference frequency (i.e J coupling constant (Hz) = IPAP difference – IPAP sum).
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Figure 38: 2D HSQC NMR spectra for 15N-labeled Fibrinogen αC (233-425) in the presence of Pf1 Phage
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In-Phase

Anti-Phase

Figure 39: Representative IPAP HSQC spectra showing peaks In-Phase (top) and Antiphase (bottom) from the 2D HSQC experiments using Fibrinogen αC (233-425)
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Sum IPAP

Difference IPAP

Figure 40: Representative Sum and Difference spectra from IPAP experiments with
Fibrinogen αC (233-425)
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To obtain RDCs, the spectral splitting for each peak was calculated from
the sum and difference for both IPAP experiments measured +/- phage. For the
peaks in the absence of the phage, typical JNH values were between 93-94 Hz.
The spectral splitting for most peaks ranged between 93-98 Hz in the presence
of phage. The difference in splittings in the presence and absence of phage are
the residual dipolar coupling (DNH) (Figure 41).
A majority of the peaks within Fibrinogen αC (233-425) have small RDCs
between 0.1-2.5 Hz. A few peaks showed negative RDC values. Interestingly,
only a couple of peaks exhibited RDCs values >4Hz (Figure 41) which potentially
indicate that the residues confer propensity for order and thus are targets for
further study. Preliminary dilution experiments with the sample containing the Pf1
phage suggest that the optimum phage concentration is approximately 18 mg/mL
substantially lower than the 31 mg/mL used in these experiment. Future studies
with this optimized phage concentration may provide further indications of more
residues that are in ordered regions. Additional studies in the presence of Factor
XIII will also highlight αC residues within Fibrinogen αC (233-425) that interact
with Factor XIII.
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Peak Numbers
Figure 41: Summary of RDCs calculated from IPAP experiments
+/- Phage in Fibrinogen αC (233-425)

With this initial success with RDC experiments, it was then necessary to
assign the HSQC peaks for each residue within Fibrinogen αC (233-425). Peak
assignments would enable the RDCs to be assigned to specific αC residues. By
knowing the identity of the peaks, residues with the potential to possess residual
structure as indicated by the RDCs could be checked for involvement with the Factor
XIII binding region.
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Preliminary 3D NMR experiments for Fibrinogen αC (233-425)
Typical peak assignment experiments with NMR spectroscopy require both
15

N and

labeled

13
15

C labeling of the protein. Our initial experiments to express the double-

N and

13

C Fibrinogen αC (233-425) using the same protocol as the

labeled protein, resulted in lower yields. For NMR studies with the

15

15

N–

N- labeled

Fibrinogen αC (233-425) yields of 2 mg/L were obtained from cultures containing
15

NH4Cl. When the same approach was used to obtain double-labeled proteins

(15NH4Cl and

13

C –glucose), the yields decreased to 0.1 mg/L. To optimize this yield,

a new approach using Bioexpress growth media was tested for both

15

N and

15

N/13C

–labeled Fibrinogen αC (233-425) described in methods above.
To test for successful expression of the
1D

13

the

15

15

N/13C Fibrinogen αC (233-425),

C-filtered HSQC experiments were performed. Figure 42 shows peaks from
N/13C –labeled protein sample at 150 µM compared to

sample at 360 µM. As expected, the

15

15

N-labeled protein

N/13C Fibrinogen αC (233-425) spectrum

showed higher peak intensities compared to spectra measured with the
labeled sample, containing a natural abundance of
additional 13C label was thus confirmed in this sample.
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13

15

N-

C. The presence of the

150 µM 15N/13C

360 µM 15N

Figure 42: Comparison of 1D 13C HSQC experiment showing improved 13C
peaks with 150 µM 15N/13C-labeled sample (cyan) compared to natural
abundance of 13C from a 360 µM sample (red) of Fibrinogen αC (233-425)

Similar patterns of clustered peaks were observed with

15

N/13C Fibrinogen

αC (233-425) in the 2D 1H-15N HSQC experiments. With the incorporation of the
13

C-label within this protein, protons attached to the

13

C could now be monitored

to assign each amino acid. In a 2D 1H-13C HSQC experiment, each peak
represents a proton attached to a

13

C. Peak clustering was observed in the

aliphatic region for experiments with

15

N/13C Fibrinogen αC (233-425). To

complete peaks assignments, 3D NMR experiments were performed to help
increase peak dispersion to levels needed for peak assignments.
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With the

15

N/13C-labeled Fibrinogen αC (233-425), it was possible to perform

3D NMR experiments to detect protons (1H) attached to both

15

N and

13

C. These

experiments make use of multiple magnetization transfers though one-bond J
coupling.119 This magnetization is then passed back to 1H for detection. In the 3D
HNCO experiment, the magnetization is transferred from the amide proton 1H to the
15

N and then to the carbonyl

13

C of the preceding amino acid (i-1) (Figure 43). This

magnetization is sequentially transferred back to the proton (1Hi) and detected as a
single peak of frequencies corresponding to HNi, Ni, COi-1 for each residue.
Significant peak clustering was observed with the 3D HNCO experiments. A
representative strip from a specific

15

N position (123.86 ppm) showed that the peaks

observed in this region are well resolved (Figure 44). Peaks in the 123.86

15

N ppm

region have higher positive RDC numbers between 2-5 Hz, making this region a good
one to monitor for changes in chemical shifts upon Factor XIII binding.
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Figure 43: Illustrated magnetization transfer for HNCO experiments (adopted from
Protein-nmr.org.uk). Representative 3D HNCO experiment from Fibrinogen αC (233425) showing position of amide proton peaks 1H-N detected in the 15N and 13C planes
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Figure 44: Representative 15N strip at 123.865 ppm showing the CO of the preceding
amino acid detected in the 3D HNCO experiment with Fibrinogen αC (233-425)

Fibrinogen αC (233-425) contains multiple glycines, serines, prolines and
threonine residues. Additional 3D experiments such as the HNCACB, HNCOCA,
and HNCA will provide information to assign these identical residues due to the
connectivities that these experiments observe. These experiments provide addition
information about the Cα and Cβ to resolve residues.
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Conclusion
Together these results suggest that Fibrinogen αC (233-425) is largely
disordered. This segment has now been doubly labeled by expression in quantities
that make these NMR experiments practical. Initial RDC measurements confirmed
that this approach could be used to identify peaks that have regions with PreSMos.
Preliminary 2D and 3D NMR experiments show a tight clustering of peaks, making
peak assignments challenging but possible with additional 3D experiments. Future
studies might focus on identifying and assigning peaks that experience significant
chemical shift changes in the presence of Factor XIII.
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CHAPTER 6
RESEARCH SUMMARY AND FUTURE DIRECTIONS
Fibrinogen is the most abundant protein involved in blood coagulation and
levels of fibrinogen have been implicated with cardiovascular disease. Fibrinogen
is a key player involved in the formation of the fibrin network that makes up blood
clots.22,

23

Blood coagulant Factor XIII functions as a transglutaminase to

introduce covalent crosslinks within the fibrin network to create a more stable clot
that is more resistant to degradation/fibrinolysis.19 For many years, the major
technique used to evaluate fibrin crosslinking has been SDS PAGE analysis.
Although this technique is efficient to quickly monitor global crosslinking trends
especially in the gamma chain of fibrinogen, very little information was obtained
about crosslinking in the alpha chain. More recently, research findings have
suggested that the alpha chain of fibrinogen contributes unique roles to the
overall clot structure and stability.86, 108, 109 The main focus of this dissertation has
been to understand fibrin crosslinking at a molecular level.
Two approaches were developed to monitor Factor XIII’s ability to
crosslink reactive glutamines in fibrinogen using a lysine mimic. A mass
spectrometry-based assay was designed whereby each reactive glutamine can
be monitored individually.48,

108

In this assay, the ability of Factor XIIIa to

incorporate a lysine mimic glycine ethyl ester into each reactive glutamine was
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monitored over time. Unlike SDS PAGE analysis, information about the role of
each individual reactive glutamine could be assessed. Moreover, the assay
provides a direct measurement of Factor XIII’s crosslinking ability as opposed to
previously designed coupled assays that rely on a secondary reaction for
detection. The second complementary instrumental approach used for this
research project was NMR spectroscopy. This time

15

N - labeled glycine ethyl

ester was used to probe Factor XIII’s ability to target reactive glutamines. Upon
crosslinking GEE to the reactive glutamine, a single peak corresponding to the
proton (1H) attached to the

15

N is observed in a 2D Heteronuclear Single

Quantum Coherence (HSQC) NMR experiment. This approach serves as a quick
test for crosslinking. However, due to the low sensitivity of the NMR instrument,
higher concentrations of protein are needed for the NMR assay compared to the
mass spectrometry approach.
In the sections that follow, findings from chapters 2, 3, 4 and 5, are
summarized along with additional plans for this research area. Future studies for
structural characterization of Fibrinogen αC (233-425) are also presented.
Furthermore, other Fibrinogen αC and γ segments that could provide additional
information on Factor XIII’s substrate specificity are discussed.

Ranking Reactive glutamines crosslinked in Fibrinogen
Previous researchers identified multiple reactive glutamines within the
Fibrinogen Aα chain that are selected by Factor XIII for crosslinking reactions.
These reactive glutamines are located mainly in the flexible αC region of
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Fibrinogen and include Q221, Q223, Q237, Q328, and Q366.82 By contrast, only
two reactive glutamines, Q398 and Q399, have been identified in the γ chain thus
far. These reactive glutamines are located in the flexible C-terminus of the
gamma chain.131 Information about the role of each reactive glutamine in
Fibrinogen has not been available. A combination of NMR spectroscopy and
mass spectrometry approaches described in Chapter 2 and 3 was used to
characterize and rank three reactive glutamines in Fibrinogen αC (233-425). Our
observations correlate with previous Factor XIII crosslinking trends reported for
full length Fibrinogen.
Fibrinogen αC (233-425) contains three reactive glutamines (Q237, Q328,
and Q366) previously identified as substrates for Factor XIII’s crosslinking
activity.57,

81

This αC segment was expressed in E.coli and purified free of the

GST- tag. Variants of Fibrinogen αC (233-425), in which reactive glutamines
were substituted for inactive asparagines, were also expressed and purified. A
MALDI-TOF mass spectrometry assay was then employed that allowed us to
monitor crosslinking over time. An NMR spectroscopy approach was also used to
assess crosslinking patterns in WT and variants of Fibrinogen αC (233-425).
From our results, the three reactive glutamines were ranked as Q237 >>
Q366 ≈ Q328. Further investigation demonstrated that at higher concentrations
of Factor XIII and longer time points, Q366 was crosslinked faster than Q328.
These rankings correlate with the crosslinking pairs previously identified in fulllength fibrinogen under the conditions studied. Wang et al., demonstrated that
Q237 can be crosslinked to up to four lysines in Fibrinogen.82 This amount was
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the most lysine pairs associated with any other reactive glutamine identified in
this study. Such an observation suggests that Q237 is playing a major role in Aα
chain crosslinking and more likely driving the unique properties associated with
crosslinking in this region. When compared to the other reactive glutamines in
this segment, Q237 is located at the N-terminus of this αC (233-425). A
combination of residue accessibility and the presence of surrounding amino acids
residues may contribute to this high selectivity for Q237 by Factor XIII. Only one
glutamine-lysine crosslinking pair was identified for Q366 and none for Q328 in
full-length fibrinogen. Compared to Q237 and Q366, Q328 is more centrally
located and it is the least reactive glutamine. Q366 is located more C-terminally
but is closer to a previously proposed binding region for Factor XIII found within
αC (389-402). This unique location could contribute to Q366 being a better
substrate than Q328.
Factor XIII’s ability to crosslink any remaining reactive glutamines
following the mutation of one or more of these reactive glutamines into an
inactive asparagine is introduced in Chapter 2, and discussed further in Chapters
3 and 4. In Fibrinogen Seoul, a single point mutation in one reactive glutamine
Q328 (AαQ328P) resulted in dysfibrinogenemia.68 Also, previous studies in which
segments of the αC containing reactive glutamines were absent showed overall
changes in clot properties and fibrin network. Together, these previous findings
suggest that the absence of one or more reactive glutamines results in altered
crosslinking properties. For the first time, it was shown that in the absence of one
or more reactive glutamine, activated Factor XIII can still crosslink any remaining
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glutamine independently.108 The absence of Q237 for example did not prevent
Factor XIII’s ability to crosslink Q366 and Q328. The same is true for Q366
located closer to the Factor XIII binding site αC (389-402). Interestingly, a Q328N
mutation also did not affect crosslinking of the other remaining reactive
glutamines. A future study with the Q328P mutation, similar to Fibrinogen Seoul
II, could provide additional information about the role of the proline in this
position.
These conclusions were made because of the ability to monitor each
reactive glutamine using MALDI-TOF mass spectrometry and NMR assays.
These assays were also applied to a segment of the gamma chain of Fibrinogen
γ (148 – 411) that contains two known remaining reactive glutamines Q398 and
Q399.132 The MALDI-TOF mass spectrometry and NMR assays demonstrated
that Factor XIIIa crosslinked both reactive glutamines within this γ segment.
Similar to reactive glutamines located on the alpha chain of Fibrinogen, the
extent to which each reactive glutamine was crosslinked differed (Chapter 2).
One reactive glutamine appeared to be crosslinked to a slightly faster extent than
the other. However, the most reactive glutamine in this γ segment could not be
identified. Future studies with mutations in this region could provide more
information about the most reactive glutamine.
It should be noted that higher concentrations of Factor XIII and longer
incubation times were needed to observe the crosslinking reaction involving
Q398 and Q399 in Fibrinogen γ(148–411) compared to the three reactive
glutamines Q237, Q328, and Q366 in Fibrinogen αC (233-425). This result is
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rather surprising since in full length Fibrinogen, crosslinking among gamma
chains is used as a quick indicator for changes in Fibrinogen crosslinking via
SDS PAGE analysis. In gel assays, γ-γ crosslinking is observed first followed by
α-α and α-γ hybrids in full-length Fibrinogen. Fibrinogen γ(148–411) segment
may have a different structural conformation that does not allow for an effective
Factor XIIIa crosslinking as in the full length γ chain.
Previous researchers have shown that the primary binding site for Factor
XIII A2B2 is located on Fibrinogen residues γ390-396.46 This region is positioned
only a few residues away from the reactive glutamines, Q398 and Q399,
identified on the gamma chain. Mice studies in which residues in Fibrinogen
γ390-396 were mutated to alanine (Fibγ390-396A) showed delayed fibrin
crosslinking and Factor XIIIa activation.133 In the presence of alanines, the
binding of Factor XIII to this region could be significantly altered. This change can
therefore affect Factor XIII’s ability to crosslink two reactive glutamines on
Fibrinogen γ chain. There is increasing evidence that Fibrinogen provides
multiple binding sites for Factor XIII on both the alpha and gamma chains.

Role of E396 and Factor XIII ability to crosslink reactive glutamines
A second binding site for Factor XIII on Fibrinogen was identified on the
Fibrinogen αC region within αC (389-402).72 The amino acid E396 was found to
be a key contributor to Factor XIII binding interactions within this region. This
conclusion was based on the observation that Factor XIII binding was
significantly decreased with the αC mutant E396A. To test for Factor XIIIa’s
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ability to crosslink reactive glutamines in the absence of this binding residue, we
introduced the E396A mutation was introduced into Fbg αC (233-425). These
results are discussed in Chapter 4.
In the presence of the E396A mutation, all three reactive glutamines were
still crosslinked by Factor XIIIa. Interestingly, these reactive glutamines were
crosslinked to a similar extent as in the wild type Fibrinogen αC (233-425).
Furthermore, a comparison of pre-activated Factor XIII A2 and Factor XIII A2
activated in the presence of Fbg αC E396A showed that all reactive glutamines
were crossliked to the same extent as in WT. The presence of the E396A
mutation thus did not affect Factor XIII A2 activation nor its crosslinking ability.
To further explore the role of E396A on Factor XIII activation, the plasma
form of Factor XIII (Factor XIII A2B2) that contains the carrier B subunit and the
catalytic A subunits was used. In the presence of the B subunits, the extent of
crosslinking was similar for all three reactive glutamines in both WT and E396A.
Curiously, a slight delay in crosslinking was observed with Factor XIII A2B2
compared to Factor XIII A2. This effect could be a result of a delay in the
activation of plasma Factor XIII A2B2 compared to the Factor XIII A2. During the
activation of Factor XIII A2B2, thrombin cleaves the activation peptide (AP) from
the A subunit, and in the presence of calcium, the B subunits dissociate from the
A subunits. This additional dissociation step required for the exposure of the
catalytic A subunit in Factor XIII A2B2 could account for the delay in activation
and subsequent crosslinking.
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Surprisingly, a recent study by Souri et al., suggests that the B subunits of
Factor XIII accelerates fibrin crosslinking.134 Normal plasma was depleted of
Factor XIII and recombinant Factor XIII A2 was added to this plasma.
Crosslinking trends in the gamma chain were monitored by SDS PAGE, with and
without Factor XIII B2 subunit. Densitometric analysis for γ-γ crosslinking
suggests that upon addition of Factor XIII B subunits, crosslinking occurs faster
compared to Factor XIII A only. It should be noted that the gels show little
evidence of crosslinking involving the alpha chain. Moveover, these results do
not correlate with our observations of alpha chain crosslinking. In our work, the
presence of the B-subunits, in plasma Factor XIII A2B2, did not accelerate
crosslinking for each reactive glutamine in Fibrinogen αC (233-425). Instead,
crosslinking in Factor XIII A2B2 was slightly delayed compared to Factor XIII A2
under the same conditions. The crosslinking trends for all three reactive
glutamines were similar for both recombinant Factor XIII A2 and plasma Factor
XIII A2B2. These differences in crosslinking extents highlight the unique
contributions of Fibrinogen crosslinking in the alpha and gamma chains. It is
possible that the γ390-396 segment is a more critical player in controlling Factor
XIII binding and activation than αC (389-402). Alternatively, the two Fibrinogen
chains contribute different regulatory roles. Future studies to distinguish the
contributions of the binding sites on the gamma and alpha chain will help in
elucidating their individual roles in Factor XIII’s activation and function.
In chapter 4, the results from unique crosslinking trends observed when
one or more reactive glutamines in Fibrinogen αC (233-425) were replaced with
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inactive asparagines are discussed. One emphasis of this study was to monitor
Q328 and Q366 in the absence of the fastest reactive glutamine Q237. Studies
later proceeded to αC (233-425) Q!N mutants with “Q328 only” and “Q366
only”. The residues Q328 and Q366 are located closest to the Factor XIII binding
site for identified within αC (389-402). For these experiments, an LC –MS method
was used to monitor these reactive glutamines because this method provided
higher throughput and sensitivity, than the MALDI-TOF MS.
Our results indicated that Q328 and Q366 were crosslinked the slowest in
αC Q237N variants. The absence of the most reactive glutamine (Q237) seems
to affect the crosslinking ability for the remaining two reactive glutamines. This
effect is still unclear since in “Q366 only”—the αC (233-425) mutant where Q237
and Q328 are replaced with inactive asparagines (Q237N/Q328N)—the
remaining reactive glutamine Q366 is crosslinked more readily than in WT.
Overall, in the absence of Q237, Q366 alone is a better substrate than Q328
alone. For short peptide substrates, Q366 may be a better candidate to examine
Factor XIII’s substrate specificity. The proximity of Q366 to the binding site and
its peculiar crosslinking trend makes it an attractive substrate for future studies.
Additional kinetic studies monitoring each reactive glutamine would provide more
information about their unique contributions in the presence of different mutation.
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Preliminary Results for the Study of αC (221-391)
Fibrinogen αC (221-391) contains two other reactive glutamines, Q221
and Q223, previously shown to be crosslinked by Factor XIIIa.114 In addition, this
protein sequence lacks the critical residue E396 and surrounding residues of the
Factor XIII binding region. Compared to Fibrinogen αC (233-425), this segment
can be used to better assess both the role of the binding region αC (389-402) for
Factor XIII and also the crosslinking ability for two additional reactive glutamines.
An attempt to express this protein using the previously optimized
approach by the Medved lab resulted in very low yields with impurities (Appendix
5). Further exploration for this αC (221-391) segment would provide useful clues
to the ability of Factor XIII to crosslink the reactive glutamines Q221 and Q223.
With an optimized mass spectrometry and NMR spectroscopy method to monitor
crosslinking, these findings would provide additional information about Factor
XIII’s substrate specificity. In the absence of the binding site αC (389-402) and
with additional reactive glutamines to select, it would be interesting to detect any
changes in the crosslinking trends for Q237, Q328, and Q366. In Fibrinogen αC
(233-425), Q237 is the most N-terminally located and the first reactive glutamine
to be crosslinked. In αC (221-391), Q221 and Q223 are additional reactive
glutamines available for crosslinking at the N-terminus. Results from the full
length Fibrinogen glutamine –lysine crosslinking pairs would suggest that Q237
would still be the fastest reactive glutamine in the presence of Q221 and Q223.82
Questions surrounding Factor XIII’s use of this binding site for crosslinking would
be answered using this αC (221-391) fragment. Changes in the reactivity of
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Q327 in the presence of Q221 and Q223 will be interesting to explore.
Information from this series of studies would elucidate the role of the additional
reactive glutamines in the N-terminus as well as Factor XIII binding site. Overall,
these findings would provide more information about Factor XIII’s selectivity and
substrate specificity.

Preliminary NMR Structural Characterization of αC (233-425)
Intrinsically disordered proteins and regions have been increasingly
associated with disease.110 In the cardiovascular disease research field,
fibrinogen has been identified as a crucial protein in the formation of stable clots.
Interestingly, a majority of the binding and crosslinking activity within fibrinogen
have been identified to occur within the flexible αC region of the Aα chain and the
flexible C-terminal portion of the γ-chain. Binding sites for Factor XIII have been
identified in flexible regions within γ390-396 and in αC (389-402). All reactive
glutamines crosslinked by Factor XIII are also located in these flexible regions
especially in the more disordered αC region. Only two reactive glutamines
located in the flexible γ-chain have been shown to be crosslinked. Although the
Bβ chain of fibrinogen contains multiple glutamines, none of these glutamines are
crosslinked by Factor XIII. A combination of accessibility and substrate specificity
is therefore important for Factor XIII’s activity.
One of the challenges in characterizing intrinsically disordered proteins
and regions is the absence of suitable techniques. NMR spectroscopy has been
adopted more recently to study these intrinsically disordered proteins (IDP). A
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unique spectral profile for IDPs is observed in 2D HSQC NMR experiments.78
This HSQC spectrum for IDPs is characterized by the narrow clustering of peaks
within the backbone amide region of the spectra (8-9 ppm) compared with a
spread of peaks for more structured proteins (6-10 ppm). This IDP type of
clustering makes it challenging to identify each amino acid residue associated
with a particular peak compared to more structurally ordered proteins where peak
clustering is less of a concern for peak identification. To aid in the assignment
process, the NMR approach requires that the protein be isotopically labeled,
which can be quite costly.
We first successfully expressed

15

N-labeled αC (233-425) and confirmed

using the 2D HSQC NMR approach that this segment is intrinsically disordered
(Chapter 5). A long range goal was then to characterize residues within the
Factor XIII binding region αC (389-402) and monitor for global changes occurring
in the presence of Factor XIII. To achieve this goal, chemical shift assignments
would be needed for this region within αC (233-425). To aid in the assignment
process, additional uniform

13

C–labeling of αC (233-425) was needed. The

conditions optimized for expressing the double-labeled

15

N/13C αC (233-425) are

described in Chapter 5. The double labeled protein sample obtained was
concentrated to 150 µM and initial NMR test experiments were performed. 1D
and 2D HSQC experiments were used to confirm the presence of both
13

15

N and

C labels on αC (233-425).
Initial results from this study are discussed in Chapter 5. Results from a

3D HNCO experiment showed few unresolved peaks. Future NMR experiments
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including HNCACO and HNCACB will provide additional information for peak
assignments. Once the assignments are complete, NMR titration experiments
can then be used to monitor changes occurring upon introducing Factor XIII. In
these experiments, the chemical shift and peak characteristics of the αC residues
will be examined. Results obtained with Factor XIII A2 and Factor XIII A2B2 can be
compared. Additional clues about Factor XIII’s binding interaction within
Fibrinogen αC (233-425) can be probed further from these studies.

Future Research to Explore Factor XIII’s substrate Specificity
In the previous chapters, Factor’s XIII ability to crosslink reactive
glutamines in the αC segment and gamma segment has been explored. The role
of a critical residue E396 as well as structural information about αC (233-425) is
now available. These findings were made possible using the design of a mass
spectrometry and NMR spectroscopy assay approaches that allow each reactive
glutamine to be monitored independently. These strategies have facilitated our
understanding of the contribution of each reactive glutamine. A similar approach
can later be applied to truncated variants of the αC region as well as the fulllength chain to gain a better understanding of crosslinking trends in this region.
Structural characterization for Fibrinogen αC (233-425) especially in the
presence of Factor XIII is another area that could provide additional clues for
Factor XIII’s substrate specificity. Previous research has sought to identify the
role of the binding region of Factor XIII. The NMR approach will provide clues to
specific residues on fibrinogen that interact with Factor XIII in both its inactivated
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and activated states. The PONDR structure predictor suggests that a few
residues within the αC (233-425) region have a propensity for order. Factor XIII
binding could promote a more ordered structure within αC (233-425).
Overall, important insights have been gained about Factor XIII’s ability to
crosslink each reactive glutamine under different conditions. Fibrinogen αC (233425) served as a good model to examine trends that have been previously
shown in full-length fibrinogen. Additional information from truncated segments of
Fibrinogen can be explored in the future to develop drugs that would be specific
for Factor XIII. Knowledge gained from this study can be used to design drugs
that are specific for Factor XIII. Since fibrinogen is the primary substrate for
Factor XIII, additional information about Factor XIII’s ability to select these
reactive glutamines can also shed light on how to design fibrinogen-based
substrates that produce a desired anticoagulant or procoagulant effect.
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APPENDIX 1
Table 1: Primers designed and used to introduce point mutations for each
reactive glutamine in Fibrinogen αC (233-425)
Mutation
Q237N
Q328N
Q366N

Forward Primer 5´-3'
ggatccacagacatgccgaacatg
agtggaaggcattaacag
ggaactggaactactggaaacaa
caaccctggaagt
tctggtagtactggaaactggcact
gtgaatctgg

Reverse Primer 5'-3'
atgccttccactcatgttcggcatgtc
tgtggatcc
ccagggttgtttccagtactcccagt
acttcc
ccagattcagagtgccagttccagt
actacc

Table 2: Sequence and mass of proteolytically derived peptides containing αC
Q237, Q328, and Q366
Reactive
Glutamine

Amino Acid Sequence

Theoretical
m/z

Experimental
m/z

Digest

Q237*
Q328

GPLGSTMPQMRME
NSGSSGTGSTGNQNPGSPRP
GSTGTWNPGSSERGSAGHW
SSVSGSTGQWHSE

1549.7
2448.1

1550
2448

GluC
chymotrypsin

1348.6

1349

GluC

Q366

*MS/MS analysis on the peptide containing Q237 revealed that amino acids
GPLGS are located just N-terminal to the αC 233-425. These amino acids remain
following PreScission protease cleavage of the GST-αC (233-425). The
sequences containing Q328 and Q366 were readily identified using a theoretical
protease digest (Protein Prospector UCSF).
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APPENDIX 2

Analysis of αC (233-425) following Protein Purification
SDS-PAGE
A 10% resolving gel was prepared by combining 4 mL deionized water (dI
H2O), 3.4 mL 30% Bis-acrylamide, 2.5 mL 1.5 M Tris (pH 8.8), and 0.1 mL 10%
SDS. Gel polymerization was initiated by adding 50 µL Ammonium persulfate
(10% APS) and 5.0 µL tetramethylethylenediamine (TEMED). This was allowed
to polymerize for 45 min. The stacking was prepared at 4% by combining 6.1 mL
dI H2O, 1.3 mL 30% Bis-acrylamide, 2.5 mL 0.5 M Tris (pH 6.8), and 0.1 mL 10%
SDS. Gel polymerization was initiated in the same way described above. This
was allowed for 30 min and wells formed were rinsed with dI H2O and running
buffer. Fractions containing αC and GST eluents were combined with nonreducing buffer, loaded on the gels, and ran at 200 V for 1 h. For c0omassie blue
staining, gels were placed in a mixture containing 0.1% coomassie blue, 40%
Methanol, 10% Acetic acid, and 50% dI H2O overnight and destained with a 40%
Methanol, 10% Acetic acid and 50% dI H2O destaining solution.
Western Blot
Western blot analysis on gels was used to confirm the presence of αC
only and no GST in the protein fractions collected after cleavage by the
PreScission™ Protease. Since αC (233-425) and GST have similar molecular
weights, SDS PAGE alone could not be assertive in distinguishing these bands.
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It was therefore important to confirm that indeed the fractions collected contained
αC (233-425) only. A similar SDS PAGE gel with fractions from αC and GST
eluents was run as previously described. This gel then subjected to western
blotting using an anti-GST-HRP Conjugate (Amersham™, GE Healthcare). All
Western Blot set-up components were equilibrated in Western Blot Transfer
buffer (25 mM Tris, 192 mM Glycine, and 20% MeOH) for 10 min at room
temperature. The gel was equilibrated as well. This was run at 100V for 1hr at
4°C and the nitrocellulose membrane obtained. Non-specific binding was
reduced by shaking the nitrocellulose membrane in a blocking solution in with 3%
BSA in PBST buffer (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.001%
Tween-20) overnight at room temperature. The gel was washed with fresh PBST
buffer and transferred to a solution containing 6µL anti-GST HRP Conjugate in
25 µL PBST. This was allowed to shake for 1 h, rinsed in PBST and developed in
TMB blotting buffer. The staining process was quenched with dIH2O.
Zip-tipping for Sample Preparation
The process of zip-tipping was done by applying all samples to a C18 ziptip for desalting. Briefly, each zip-tip was rinsed using 4 µL (3x) in 100%
acetonitrile, followed by equilibration in 0.1% TFA (4 µL, 3x). The sample was
applied on the zip-tip by pipeting up and down at least 8 times. The unbound
material where rinsed using 0.1% TFA (5 µL, 3x). For sample digested with
chymotrypsin, the zip-tipped samples were eluted in 5 µL α-cyano-4hydroxycinnamic acid (αCHCA) matrix (13 mg/ml dissolved in 0.1% TFA,
acetonitrile, and ethanol) by pipeting up and down. GluC digested samples were
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eluted in 5 µL ferulic acid matrix. 1 µL of each sample was spotted on the MALDI
plate. The MALDI-TOF was operated under positive reflectron mode at an
optimized manual laser intensity of 1997. Peptide fragments observed were
compared to theoretical digests from chymotrypsin and GluC and the peptide
peaks containing reactive glutamines were identified. Under crosslinking
conditions, peaks containing reactive glutamines and crosslinked to GEE were
observed at an additional 86 m/z. Peaks heights for reactant and product peaks
were extracted using the Data Explorer analyzer.
Mutations within αC (233-425) confirmed using MALDI TOF Mass
Spectrometry
Mutations introduced in αC (233-425) were confirmed using DNA
sequencing. Following protein purification, the presence of the desired mutation
was verified using the MALDI-TOF mass spectrometry. Chymotrypsin digest was
used to confirm the presence of Q328N mutation. Meanwhile, peaks identified
from the GluC digests of αC (233-425) allowed us to confirm the presence of Q
to N mutations in Q237 and Q366 and Q328 as well as the E396A mutation.

Mutation

Digested Peptide Fragment

m/z

m/z (wt)

Q237N

GPLGSTDMPNMRM

1535

1550

Q328N

NSGSSGTGSTGNNNPGPRPGSTGTW

2347

2448

Q366N

SSVSGSTGNWHSE

1334

1349

E396A

SGSFRPDSPGSGNARPNNPDWGTFAE 2647

2776
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APPENDIX 3

Validating αC (233-425) crosslinking with
1

15

N-labeled substrates using 2D

H - 15N HSQC NMR spectroscopy
The exchange of

15

N-labeled NH4Cl and crosslinking of

with αC (233-425) was monitored using a

15

15

N-labeled GEE

N- heteronuclear single quantum

coherence (HSQC) NMR spectroscopy. All assays were carried out in had a total
volume of 400 µL with a 10% v/v D2O added for a deuterium lock on the NMR
instrument. For the

15

N-labeled NH4Cl exchange reactions, 400 nM FXIII was

non-proteolytically activated in the presence of excess calcium (50 mM) and
20mM borate buffer (pH 8) for 10 min at 37°C. Then, 100 mM 15NH4Cl and 40 µM
αC (233-425) were added and the mixture incubated for 1hr at 37°C. For
crosslinking reactions with

15

N-labeled GEE, 800 nM FXIII was proteolytically

activated with 21 U/ml bovine thrombin in presence of 5 mM CaCl2 and 20 mM
Borate buffer. Thrombin was quenched with 460 nM PPACK. 10 mM

15

N-labeled

GEE and 35 µM αC (233-425) was added and incubated for 1 h at 37°C. D2O
was added and the mixture transferred to a Shigemi NMR tube. These were
analysed on a Varian 700Hz NMR Instrument. The parameters for the 1D HSQC
were nt =512, ni = 1, np =2048, and the 2D HSQC nt =64, ni = 64, np = 2048.
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2D

15

N HSQC NMR spectrum of αC (233-425) incorporating

15

N-labeled

NH4Cl in the presence of Ca2+ activated FXIII shows three peaks with
corresponding crosspeaks. A similar 2D

15

N HSQC NMR spectrum obtained

from the crosslinking reaction of reactive glutamines on αC (233-425) and

15

N-

labeled GEE catalyzed by thrombin-activated FXIII showed three distinct peaks.
All reaction schemes for the crosslinking of αC (233-425) with labeled substrates
are also shown.
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APPENDIX 4
Monitoring Factor XIII A2 and Factor XIII A2B2 activation

FXIII A2

FXIII A2B2

Thrombin activation of Factor XIII A2 and Factor XIII A2B2 in the presence
of used in Chapter 4 were monitored for over time (top and bottom gels
respectively). Each gel contains Molecular weight marker and aliquots obtained
from time points 0, 1, 2, 5, 10, 15, 30 and 60 minutes respectively. The last lane
represents inactivated Factor XIII A2 and Factor XIII A2B2 for each gel. Factor
XIII: Thrombin ratios used for these gels were 60.9: 1 for Factor XIII A2 and 15.1:
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1 Factor XIII A2B2. In both cases, over 50% Factor XIII was activated within 5
minutes of the reaction.
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APPENDIX 5
Protein Expression of αC (221-391)
pET20b vector containing cDNA with αC 221-391 was a generous gift
obtained from Dr. Leonid Medved (University of Maryland). For specific
purification and to isolate only our protein of interest, this DNA was inserted into
a pET14b vector with a His tag and sumo protease encoding region. The
following primers were designed containing NdeI and HindIII restriction sites.
Forward 5’-GGGAATTCCATATGCAGCTGCAGAAA- 3’ and Reverse primer 5’CGCGGATCCTTACCAATCCGGGTTGTCGG -3’. These primers were used to
amplify the cDNA encoding for αC 221-391. For the PCR reactions, 200 µM
dNTP, 500 nM forward and reverse primers, 112 ng DNA, and 5X Phusion HF
buffer (10 µL) were combined. Phusion DNA polymerase (0.5 µL) was added to
the mixture and the final volume adjusted to 50 µL with dI water. The following
parameters were optimized to amplification; initial denaturation (98°C for 30 sec);
Repeated 30 cycles (98°C for 10 sec, 70°C for 25 sec, and 72°C for 25 sec); and
final extension (72°C for 10 min) and final hold for 4°C. The PCR product was
separated on an agarose gel (1%) and the desired band (~600bp) was cut and
isolated following ethidium bromide staining.
To obtain high yield and purity for this protein, the DNA was inserted into a
pET14b vector containing a HisTag and a SUMO protease encoding region. The
HisTag provides a tag sequence for more specific affinity column protein
purification. The SUMO protease is strategically located between the HisTag and
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the cDNA for the αC (221-391) protein. SUMO protease cleavage will result in
the release of only the αC (221-391) segment and first residue in this αC
segment will be the reactive glutamine Q221. For better comparisons with the
natural αC sequence, it is important to characterize Q221 free from the HisTag
and the SUMO protease segment.
To amplify and extract the cDNA region for αC (221-391) from the original
pET20b vector, primers were designed containing BamHI and NdeIII were used.
This cDNA was ligated into the pET14b vector and transformed into BL21 Gold
DE3 cells. An initial expression test was performed using for optimal conditions
needed for IPTG induction. A small scale protein purification was performed. Our
preliminary results from purifying αC (221-391) with the both the HisTag and
SUMO protease still present, showed high levels of impurities. Gel analysis
showed multiple bands from other affinity binding protein. These impurities have
a high affinity for the HisTrap column as well. The next strategy will be to add the
SUMO protease cleaving enzyme on-column as in our GST-tagged system.
Future investigations will optimize the conditions for high yields with low
impurities in this segment.
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